503 results on '"Damjanov N"'
Search Results
202. Does childhood health assessment questionnaire can predict outcome of patients with juvenile idiopathic arthritis?
- Author
-
Susic, G, primary, Stojanovic, R, additional, Soldatovic, I, additional, Damjanov, N, additional, and Radunovic, G, additional
- Published
- 2011
- Full Text
- View/download PDF
203. PS1-33 Safety and efficacy of ITF2357, an orally active histone deacetylase inhibitor in the treatment of systemic onset juvenile idiopathic arthritis
- Author
-
Vojinovic, J., primary, Damjanov, N., additional, Furlan, A., additional, D’Urzo, C., additional, Susic, G., additional, Pasic, S., additional, Iagaru, N., additional, Stefan, M., additional, and Dinarello, C.A., additional
- Published
- 2010
- Full Text
- View/download PDF
204. Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study.
- Author
-
Sun, W., primary, Mykulowycz, K., additional, Teitelbaum, U. R., additional, Damjanov, N., additional, Haller, D. G., additional, Giantonio, B. J., additional, Carberry, M., additional, and O'Dwyer, P. J., additional
- Published
- 2010
- Full Text
- View/download PDF
205. PMS56 ACCESS TO BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS IN CENTRAL AND EASTERN EUROPEAN (CEE) COUNTRIES
- Author
-
Orlewska, E, primary, Ancuta, I, additional, Anic, B, additional, Codreanu, C, additional, Damjanov, N, additional, Djukic, P, additional, Gulacsi, L, additional, Ionescu, R, additional, Marinchev, L, additional, Nasonov, EL, additional, Pentek, M, additional, Praprotnik, S, additional, Rashkov, R, additional, Skoupa, J, additional, Tlustochowicz, W, additional, Tlustochowicz, M, additional, Tomsic, M, additional, Veldi, T, additional, Vojinovic, J, additional, and Wiland, P, additional
- Published
- 2010
- Full Text
- View/download PDF
206. Body composition estimated by DXA scan in patients with systemic sclerosis
- Author
-
Gavrilov⁎, N., primary, Pilipović, N., additional, Simić-Pašalić, K., additional, Radunović, G., additional, and Damjanov, N., additional
- Published
- 2009
- Full Text
- View/download PDF
207. Induced Sputum in Systemic Sclerosis Interstitial Lung Disease: Comparison to Healthy Controls and Bronchoalveolar Lavage
- Author
-
Damjanov, N., primary, Ostojic, P., additional, Kaloudi, O., additional, Alari, S., additional, Guiducci, S., additional, Stanflin, N., additional, Nestorovic, B., additional, Knezevic, J., additional, Camiciottoli, G., additional, Porta, F., additional, Pistolesi, M., additional, Ibba-Manneschi, L., additional, Conforti, M.L., additional, Candelieri, A., additional, and Matucci Cerinic, M., additional
- Published
- 2008
- Full Text
- View/download PDF
208. DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
- Author
-
Vojinovic, J, primary, Basic, J, additional, Susic, G, additional, Jevtovic-Stoimenov, T, additional, Damjanov, N, additional, and Pavlovic, D, additional
- Published
- 2008
- Full Text
- View/download PDF
209. Frequency of risk factors for gastro-intestinal bleeding in 9704 patients using non-steroid anti-inflammatory drugs (NSAID's), treated in general practice in 2005. and 2006
- Author
-
Babic, G., primary, Damjanov, N., additional, and Radunovic, G., additional
- Published
- 2008
- Full Text
- View/download PDF
210. Modeling and simulation of neutropenia to support dosing regimens for liposome-encapsulated paclitaxel easy-to-use (LEP- ETU)
- Author
-
Grasela, T. H., primary, Fetterly, G. J., additional, Dul, J. L., additional, LeComte, D., additional, Grahn, A. Y., additional, Fiedler-Kelly, J. B., additional, Sherman, J. W., additional, Damjanov, N., additional, Fishman, M. N., additional, and Tan, A. R., additional
- Published
- 2007
- Full Text
- View/download PDF
211. Psychosocial barriers to clinical trial participation as perceived by oncologists and patients
- Author
-
Meropol, N. J., primary, Buzaglo, J. S., additional, Millard, J. L., additional, Ridgway, C. G., additional, Damjanov, N., additional, Miller, S. M., additional, Ross, E. A., additional, Sprandio, J. D., additional, and Watts, P., additional
- Published
- 2005
- Full Text
- View/download PDF
212. Final results of a Phase I study of Liposome Entrapped Paclitaxel (LEP-ETU) in patients with advanced cancer
- Author
-
Damjanov, N., primary, Fishman, M. N., additional, Steinberg, J. L., additional, Fetterly, G. J., additional, Haas, A., additional, Grahn, A., additional, Lauay, C., additional, Dul, J. L., additional, Sherman, J. W., additional, and Rubin, E. H., additional
- Published
- 2005
- Full Text
- View/download PDF
213. EGFR activation of IGF-IR in normal and malignant hepatocytes
- Author
-
Hallak, H., primary and Damjanov, N., additional
- Published
- 2005
- Full Text
- View/download PDF
214. Racial variation in pancreatic adenocarcinoma?An urban university experience
- Author
-
GAUGHAN, C, primary, DEMPSEY, D, additional, DAMJANOV, N, additional, and PARIKH, A, additional
- Published
- 2005
- Full Text
- View/download PDF
215. Phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer
- Author
-
Fishman, M. N., primary, Elsayed, Y., additional, Damjanov, N., additional, Steinberg, J. L., additional, Mahany, J. J., additional, Nieves, J. A., additional, Wanaski, S. P., additional, Dul, J. L., additional, and Sherman, J. W., additional
- Published
- 2004
- Full Text
- View/download PDF
216. AB0111 Prognostic significance of limited and difusse form of skin changes in systemic sclerosis
- Author
-
Damjanov, N, primary, Dobrosavljevic, G, additional, Pavlov, S, additional, Radunovic, G, additional, Djurdjic, I, additional, Todorvic, N, additional, Milenkovic, M, additional, and Ostojic, P, additional
- Published
- 2001
- Full Text
- View/download PDF
217. FRI0133 Outcome and prognostic factors for lupus nephritis in sle patients treated with “small puls” of cyclophosphamide: follow-up study 1985–1999
- Author
-
Stojanovic, RM, primary, Gacic, D, additional, Palic-Obradovic, D, additional, Blagojevic-Lazic, R, additional, Susic, G, additional, Damjanov, N, additional, Stevanovic, G, additional, Mircetic, V, additional, Jeftic, M, additional, and Budimir, M, additional
- Published
- 2001
- Full Text
- View/download PDF
218. Phase I trial in advanced malignancies with Liposome Encapsulated Paclitaxel (LEP)
- Author
-
Treat, J.A, primary, Huang, C, additional, Damjanov, N, additional, Walker, S, additional, Drobins, P, additional, Gokhale, P, additional, Kopreski, M, additional, Massimini, G, additional, and Rahman, A, additional
- Published
- 2000
- Full Text
- View/download PDF
219. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies.
- Author
-
Damjanov N, Kauffman RS, and Spencer-Green GT
- Abstract
OBJECTIVE: To assess the efficacy and safety of VX-702, a p38 MAPK inhibitor, in patients with active, moderate-to-severe rheumatoid arthritis (RA). METHODS: Two 12-week, double-blind, placebo-controlled studies of VX-702 were conducted in patients with active, moderate-to-severe RA. In the VeRA study, 313 patients received placebo or 2 daily doses of VX-702. In Study 304, 117 patients received placebo, daily VX-702, or twice weekly VX-702 in addition to concomitant methotrexate (MTX). Study end points included the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (an ACR20 response), ACR50 and ACR70 responses, changes in the serum levels of biomarkers of inflammation, and safety assessments. RESULTS: The numerically superior ACR20 response rates among patients receiving VX-702 compared with those receiving placebo in both studies did not reach pairwise statistical significance at the highest doses in either study. At week 12 in the VeRA study, ACR20 response rates were 40%, 36%, and 28% among patients receiving 10 mg of VX-702, 5 mg of VX-702, and placebo, respectively. In Study 304, the response rates were 40%, 44%, and 22% for patients receiving 10 mg VX-702 daily plus MTX, 10 mg VX-702 twice weekly plus MTX, and placebo, respectively. Reductions in the levels of C-reactive protein, soluble tumor necrosis factor receptor p55, and serum amyloid A were observed as early as week 1 in both studies, but these levels rapidly returned to baseline values by week 4. The overall frequency of adverse events was similar between the VX-702 and placebo groups. In the VeRA study, serious infections were more frequent in the VX-702 groups compared with the placebo group (2.4% versus 0%) but not in Study 304 (2.6% versus 4.9%). CONCLUSION: The modest clinical efficacy plus the transient suppression of biomarkers of inflammation observed in this study suggest that p38 MAPK inhibition may not provide meaningful, sustained suppression of the chronic inflammation seen in RA. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
220. Recommendation for gastroprotection in gastrointestinal bleeding prevention
- Author
-
Damjanov Nemanja, Vukčević Vladan, Krstić Miodrag, Milosavljević Tomica, Jeremić Ivica, and Sokić-Milutinović Aleksandra
- Subjects
gastrointestinal bleeding ,nonsteroidal anti-inflammatory drugs ,gastric acid ,Medicine - Abstract
Incidence of gastrointestinal bleeding in most populations is about 1 per 1,000 inhabitants. More than 65% of all bleeding episodes are associated with drug use. The most often involved are non-steroidal antiinflammatory drugs and low doses of acetyl-salicylic acid. The mortality within the first month after the bleeding episode is about 10-12%, and has not significantly changed in the last decade. Therefore, bleeding prevention is of major importance. Appropriate selection of patients, proper drug choice, application of lowest efficient doses of potentially ulcerogenic drugs, and use of drugs that inhibit gastric acid secretion remain cornerstone preventive measures of gastrointestinal bleeding.
- Published
- 2016
- Full Text
- View/download PDF
221. Alfacalcidol modulates oxidative stress parameters in the peripheral blood of patients with active rheumatoid arthritis
- Author
-
Živanović-Radnić Tatjana, Simić-Pašalić Katarina, Šefik-Bukilica Mirjana, Misirlić-Denčić Sonja, Isaković Anđelka M., Stojković Tihomir, Petronijević Nataša, Damjanov Nemanja, and Vojinović Jelena
- Subjects
antioxidant activity ,disease activity ,additional therapy ,beneficial ,PBMC ,Chemistry ,QD1-999 - Abstract
Hormone D and its analogues display immunomodulatory activities providing a beneficial effect in immunoinflammatory diseases. The aim of this study was to assess the effect of alfacalcidol treatment on superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) activity and glutathione (GSH) and malondialdehyde (MDA) levels in patients with active RA. Sixteen patients with active RA and twenty controls were enrolled in the study. Blood samples were taken before and after 12 weeks of alfacalcidol therapy (2 μg/day). Oxidative stress parameters were determined spectrophotometrically and by flow cytometry assessment. Disease activity was assessed using DAS28 score. The results revealed that alfacalcidol treatment, significantly (p = 0.04) reduced SOD activity and CAT activity (p = 0.001) in RA patients. The activity of GPx was significantly lower in RA patients before treatment, compared to controls (p = 0.04). After therapy, GPx activity was restored to control levels, and GSH levels were significantly reduced (p = 0.01). MDA levels in patients at the beginning of the study protocol, remained significantly elevated compared to controls (p = 0.01). Alfacalcidol treatment decreased MDA levels in patients (p = 0.19). Furthermore, 12-weeks alfacalcidol therapy, changed the response of RA patients’ PBMC to stimulation preventing the O2 - production and mitochondrial membrane depolarisation. After alfacalcidol treatment, significant clinical improvement was observed.
- Published
- 2016
- Full Text
- View/download PDF
222. Influence of promoter polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) genes on therapeutic response to etanercept in rheumatoid arthritis
- Author
-
Jančić Ivan, Šefik-Bukilica Mirjana, Živojinović Slađana, Damjanov Nemanja, Spasovski Vesna, Kotur Nikola, Klaassen Kristel, Pavlović Sonja, Bufan Biljana, and Arsenović-Ranin Nevena
- Subjects
etanercept ,pharmacogenetics ,rheumatoid arthritis ,308g/a tnf-α gene polymorphism ,174g/c il-6 gene polymorphism ,Biochemistry ,QD415-436 - Abstract
Background: The study was undertaken to assess the influence of functional -308G /A TNF-α (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-α blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G /A TNF-α and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement > 1.2) between patients with the TNF-α -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/TNF-α genotypes showed that patients with the IL-6 -174GG / TNF-α -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chisquare test). More precisely, all patients with the combined IL-6 -174GG / TNF-α -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-α and IL-6 producers are the best responders to etanercept therapy.
- Published
- 2015
223. What's the 'take home'? Pearls from clinical cases. Middle-Aged woman with thyroid nodules.
- Author
-
Damjanov N and Rubin RN
- Published
- 2005
224. The clinical significance of antibody determination to cyclic citrullinated peptides in systemic sclerosis
- Author
-
Stamenković Bojana, Stanković Aleksandra, Dimić Aleksandar, Damjanov Nemanja, Nedović Jovan, Stojanović Sonja, Savić Vojin, and Đorđević Dragan
- Subjects
anti-citrullinated peptide antibodies ,systemic sclerosis ,arthritis ,erosions ,Medicine - Abstract
Introduction. Anti-citrullinated peptides antibodies (ACPA) are present in 80% of sera of rheumatoid arthritis (RA) patients with high specificity for diagnosis and prediction for the development of early erosive arthritis. A few studies have reported a low frequency ACPA in systemic sclerosis (SSc) patients with the presence of arthritis. Objective. The aim of our study was to determine the frequency of ACPA in systemic sclerosis (SSc) patients, their correlation with clinical manifestations and radiographic features. Methods. The study included 82 patients with SSc, mean age 54.4 years, 59 with the limited (lSSc) and 23 with the diffuse (dSSc) form of the disease. The control group included 28 healthy age and sex matched subjects. ACPA and rheumatoid factor (RF) were determined in all SSc patients and healthy subjects in whom standard radiography of hands and wrists was also done. Results. The presence of ACPA was detected in 11 (13.4%) of SSc patients. Their level was not increased in any of the controls. Positive RF was found in 15.9% of SSc patients. Arthritis was present in 17.1%, as well as marginal bone erosions. There was a statistically significant association between positive ACPA and arthritis (p
- Published
- 2012
- Full Text
- View/download PDF
225. Biologic therapy of rheumatoid arthritis
- Author
-
Damjanov Nemanja and Vojinović Jelena
- Subjects
rheumatoid arthritis ,juvenile idiopathic arthritis ,biologic therapy ,Medicine - Abstract
Rheumatoid arthritis (RA) and juvenile idiopathic/rheumatoid arthritis (JIA) are chronic, inflammatory, systemic, auto-immune diseases characterized by chronic arthritis leading to progressive joint erosions. The individual functional and social impact of rheumatoid arthritis is of great importance. Disability and joint damage occur rapidly and early in the course of the disease. The remarkably improved outcomes have been achieved initiating biologic therapy with close monitoring of disease progression. Biologic agents are drugs, usually proteins, which can influence chronic immune dysregulation resulting in chronic arthritis. According to the mechanism of action these drugs include: 1) anti-TNF drugs (etanercept, infiximab, adalimumab); 2) IL-1 blocking drugs (anakinra); 3) IL-6 blocking drugs (tocilizumab); 4) agents blocking selective co-stimulation modulation (abatacept); 5) CD 20 blocking drugs (rituximab). Biologics targeting TNF-alpha with methotrexate have revolutionized the treatment of RA, producing significant improvement in clinical, radiographic, and functional outcomes not seen previously. The new concept of rheumatoid arthritis treatment defines early diagnosis, early aggressive therapy with optimal doses of disease modifying antirheumatic drugs (DMARDs) and, if no improvement has been achieved during six months, early introduction of biologic drugs. The three-year experience of biologic therapy in Serbia has shown a positive effect on disease outcome.
- Published
- 2009
- Full Text
- View/download PDF
226. Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors
- Author
-
Mandić Dragana, Ćurčić Radmila, Radosavljević Gordana, Damjanov Nemanja, Stefanović Dušan, Mitić Igor, and Dimić Aleksandar
- Subjects
tuberculosis ,screening ,tumour necrosis factor ,PPD ,Medicine - Abstract
Patients with an autoimmune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis, uveitis or psoriasis, and treated with the anti-tumour necrosis factor (TNF) alpha inhibitors are at high risk of developing various infections including tuberculosis (TB). Serious infections are the result of the patients' immunocompromised status that is caused by the primary disease itself, as well as by previous immunosuppressive therapy. In order to decrease the risk of developing TB, prior to the introduction of the anti-TNF alpha therapy, all patients should undergo screening for TB. Experiences from the countries that have already implemented recommendations for TB screening show a significant decrease in TB occurrence in the anti-TNF alpha treated patients. The PPD skin test result is considered positive if induration is of size ≥5 mm. The BCG vaccine applied at birth has no effect on interpretation of PPD test results in adults. The diagnosis of active TB is contraindicated for the introduction of the anti-TNF alpha therapy; first, such patients should receive the TB treatment; and 6 months after the completion of the TB treatment, the introduction of the anti-TNF alpha therapy may be considered. The patients with the diagnosis of the latent TB infection (LTBI) should not immediately start with the anti-TNF alpha therapy, but they should first receive the TB chemoprophylaxis; not earlier than a month upon the introduction of the TB chemoprophylaxis, the anti-TNF alpha therapy may be introduced. The first TB follow-up screening during the anti-TNF alpha therapy is recommended 6 months after the anti-TNF alpha therapy has been introduced and the next one should be scheduled after 12 months.
- Published
- 2009
- Full Text
- View/download PDF
227. Cholestatic hepatitis associated with nimesulide: A case report
- Author
-
Lukić Snežana, Krstić Miodrag, Damjanov Nemanja, Boričić Ivan, Popović Dragan, Đuranović Srđan, Kovačević Nada, and Tomanović Nada
- Subjects
cholestatic hepatitis ,non-steroidal anti-inflammatory drugs ,nimesulide ,hepatotoxicity ,Medicine - Abstract
Introduction A toxic effect of drugs, including non-steroidal anti-inflammatory drugs, may be one of aetiological factors for the occurrence of acute hepatitis. Nimesulide is a selective cyclooxygenase-2 inhibitor, whose adverse effects on the liver range from acute hepatitis to more serious conditions, involving the development of acute liver failure and fatal outcome. Case Outline A female patient, aged 73, was admitted to the Gastroenterology and Hepatology Clinic of the Clinical Centre of Serbia in Belgrade because of liver failure. Due to the pain in the right knee, she received a therapy of 100 mg nimesulide in tablets, two times a day, for two months before admission to the Clinic. The analysis of the results of clinical, laboratory and radiographic examinations, and of histopathological findings of the liver biopsy showed that acute hepatitis was associated with the administration of nimesulide. Once the patient discontinued the intake of this drug, she fully convalesced. Conclusion The patient who received nimesulide over a period of two months developed acute hepatitis. In view of the similar cases described in literature and the fact that the use of nimesulide has been discontinued in a number of European countries and restricted by the European Medicines Agency, restriction or ban on the use of nimesulide on the Serbian market should be considered.
- Published
- 2009
- Full Text
- View/download PDF
228. EULAR recommendations for the managements of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 Update,Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi: Aktualizácia 2013
- Author
-
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., Ramiro, S., Winthrop, K., Wit, M., Aletaha, D., Betteridge, N., Bijlsma, J. W. J., Boers, M., Buttgereit, F., Combe, B., Cutolo, M., Damjanov, N., Hazes, J. M. W., Kouloumas, M., Kvien, T. K., Mariette, X., Karel Pavelka, Riel, P. L. C. M., Rubbert-Roth, A., Scholte-Voshaar, M., Scott, D. L., Sokka-Isler, T., Wong, J. B., and Heijde, D.
229. Development of ultrasound enthesitis score to identify patients with enthesitis having spondyloarthritis: prospective, double-blinded, controlled study
- Author
-
Milutinovic, S., Radunovic, G., Veljkovic, K., Zlatanovic, M., Zlatkovic Svenda, M., Perovic Radak, M., Pavlov Dolijanovic, S., Stojic, B., and Damjanov, N.
230. Induced sputum: A non-invasive tool for evaluation of lung involvement and alveolar inflammation in systemic sclerosis
- Author
-
Cerinic, M. Matucci, Pignone, A. Moggi, PAOLO SFRISO, Cozzi, F., Conforti, M., Pistolesi, M., Meoni, E., Porta, F., Camiciottoli, G., Knezevic, J., Nestorovic, B., Orsi, S., Stanflin, N., Del Rosso, A., Guiducci, S., Cinelli, M., Alari, S., Kaloudi, O., Ostojic, P., and Damjanov, N. S.
231. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis
- Author
-
Milic, V., Jekic, B., Lukovic, L., Bunjevacki, V., Milasin, J., Novakovic, I., Damnjanovic, T., Popovic, B., Maksimovic, N., Damjanov, N., Radunovic, G., Nada Pejnović, and Krajinovic, M.
- Subjects
musculoskeletal diseases ,rheumatoid ,ATIC ,DHFR ,skin and connective tissue diseases ,polymorphisms ,methotrexate - Abstract
Objectives Identifying genetic predictors of methotrexate (MTX) treatment response in patients with rheumatoid arthritis (RA) may have great importance for optimising drug doses required for clinical benefit without toxicity. In a group of 125 RA patients treated with MTX we investigated whether selected polymorphisms in genes relevant for MTX action (aminoimidazole-4-carboxiamide ribonucleotide transformylase, ATIC, and dihydrofolate reductase, DHFR) modulate disease activity and/or have impact on therapy side effects. Methods The efficacy of treatment was estimated both by the disease activity score in 28 joints (DAS28), based on EULAR criteria, and relative DAS28 (rDAS28) score. Adverse drug events (ADEs) were also recorded. RA patients were genotyped using the PCR-RFLP method, followed by an association study between ATIC -129T>G, DHFR -216T>C and DHFR -317A>G polymorphisms and the efficacy and toxicity of MTX. Results According to the EULAR response criteria, 96 RA patients (76.8%) were classified as responders (good/moderate response) and 29 (23.2%) as non-responders (poor response). rDAS28 values ranged from -0.01 to 0.80 (mean value 0.31 +/- 0.19). Among 125 patients enrolled in this study 39 experienced at least one side effect. The DHFR -317AA genotype was associated with the less favourable response (reduction in rDAS28 score, p=0.05). None of the analysed polymorphisms was associated with MTX toxicity. Conclusion RA patients with DHFR-317AA genotype had less favourable response to MTX Further studies in larger patient populations are necessary to confirm the relationship between the analysed polymorphisms and MTX treatment response.
232. Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis
- Author
-
Patricia E Carreira, Carmona, L., Joven, B. E., Loza, E., Andreu, J. L., Riemekasten, G., Vettori, S., Allanore, Y., Balbir-Gurman, A., Airò, P., Walker, U. A., Damjanov, N., Ananieva, L. P., Rednic, S., Czirják, L., Distler, O., Farge, D., Hesselstrand, R., Corrado, A., Caramaschi, P., Tikly, M., Matucci-Cerinic, M., Carreira, Patricia E., Carmona, Loreto, Joven, Beatriz E., Loza, Estibaliz, Andreu, Josã© Lui, Riemekasten, Gabriela, Vettori, Serena, Allanore, Yannick, Balbir gurman, Alexandra, Airã², Paolo, Walker, Ulrich A., Damjanov, Nemanja, Ananieva, Lidia P., Rednic, Simona, Czirjã¡k, Lã¡szlã³, Distler, Oliver, Farge, Dominique, Hesselstrand, Roger, Corrado, Ada, Caramaschi, Paola, Tikly, Mohammed, and Matucci cerinic, Marco
- Subjects
Adult ,Male ,Scleroderma, Systemic ,Systole ,Immunology ,Middle Aged ,Pulmonary Artery ,Pulmonary arterial hypertension ,Echocardiography, Doppler ,Systemic sclerosi ,Cross-Sectional Studies ,Logistic Models ,Rheumatology ,Right heart catheterisation ,Echocardiography ,Immunology and Allergy ,Humans ,Female ,Aged - Abstract
Objective. To explore the prevalence and clinical associations of elevated systolic pulmonary artery pressure (sPAP), measured by Transthoracic Dopplerechocardiography (TTE) in patients with early systemic sclerosis (SSc). Methods. A cross-sectional analysis of the prospective EULAR Scleroderma Trial and Research (EUSTAR) database was performed. SSc patients with < 3 years from the first non-Raynaud's phenomenon (RP) symptom at baseline EUSTAR visit, were selected. Elevated sPAP was defined as sPAP > 40 mmHg on baseline TTE. First visit SSc related variables, including disease subsets, antibodies and visceral involvement, were examined. Results. From 1,188 patients, 81% were women. Mean (SD) age at first non-RP symptom was 50 (14) years, 55% had limited cutaneous SSc (lcSSc) and 42% active disease. Elevated sPAP was found in 17% of patients, both lcSSc and diffuse cutaneous SSc (dc- SSc). In lcSSc, older age at first non- RP symptom, ACA positivity, joint contractures, restrictive defect and lower DLCO, were independently associated with elevated sPAP. In dcSSc, older age at first non-RP symptom, longer time between RP onset and first non-RP symptom, digital ulcers, cardiac blocks, and proteinuria were associated with elevated sPAP. Conclusion. The prevalence of elevated sPAP on TTE in early SSc patients is considerable. Association with cardiac, lung and renal involvement suggests that, although some patients might have pulmonary arterial hypertension, others may present pulmonary hypertension secondary to lung or heart involvement. Our findings emphasise the need to consider right heart catheterisation in selected early SSc patients with PH suspicion, to clearly determine the cause of PH.
233. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: A prospective outcome study
- Author
-
Susic, G. Z., Stojanovic, R. M., Nada Pejnović, Damjanov, N. S., Soldatovic, I. I., Jablanovic, D. B., and Sefik Bukilica, M. N.
234. Women's health and fertility, family planning and pregnancy in immune-mediated rheumatic diseases: A report from a south-eastern European Expert Meeting
- Author
-
Ntali, S., Damjanov, N., Drakakis, P., Ionescu, R., Kalinova, D., Rashkov, R., Malamitsi-Puchner, A., Mantzaris, G., Lina Michala, Pamfil, C., Rednic, S., Tektonidou, M. G., Tsiodras, S., Vassilopoulos, D., Vojinovic, J., Bertsias, G. K., and Boumpas, D. T.
235. Über die Struktur und einige Eigenschaften von mit Tetrachlorchinon plastifiziertem Polystyrol
- Author
-
Damjanov, S. S., primary, Kartalov, P. S., additional, Damjanov, N. S., additional, and Polisov, Ch. T., additional
- Published
- 1976
- Full Text
- View/download PDF
236. Watermelon stomach in a patient with primary Sjögren's syndrome
- Author
-
Krstić Miodrag, Alempijević Tamara, Andrejević Slađana, Zlatanović Maja, Damjanov Nemanja, Ivanović Branislava, Jovanović Ivan, Tarabar Dino, and Milosavljević Tomica
- Subjects
Sjogren's syndrome ,gastral antral vascular ectasia ,anemia, iron-deficiency ,drug therapy ,treatment outcome ,Medicine (General) ,R5-920 - Abstract
Introduction. Watermelon stomach (WS) or gastric antral vascular ectasia (GAVE) is a rare cause of upper gastrointestinal bleeding described in a variety of autoimmune disorders. Association of watermelon stomach with Sjögren's syndrome is extremely rare. Case report. We presented a 67-year old female with primary Sjögren's syndrome (SS) who had developed a persistent severe iron-deficiency anemia. An upper gastric endoscopy revealed the presence of gastric antral vascular ectasia (GAVE) as a cause of occult gastrointestinal bleeding. The treatment with argon-plasma coagulation was postponed as the conservative therapy with iron substitution and proton pump inhibitor led to improvement of anemia and hemoglobin levels normalization. Conclusion. This is the first report of WS in a patient with primary SS without the presence of coexisting autoimmune disorder. Recognition of this rare, but clinically important, cause of gastrointestinal bleeding may decrease comorbidity in patients with autoimmune disorders including primary Sjögren's syndrome.
- Published
- 2010
- Full Text
- View/download PDF
237. What's the 'take home'?
- Author
-
Damjanov N, Dunphy E, Moyer D, and Rubin RN
- Published
- 2007
238. EULAR/eumusc.net standards of care for rheumatoid arthritis
- Author
-
Rachelle, Meisters, Polina, Putrik, Sofia, Ramiro, Monika, Hifinger, Andras P, Keszei, Yvonne, van Eijk-Hustings, Anthony D, Woolf, Josef S, Smolen, Tanja A, Stamm, Michaela, Stoffer-Marx, Till, Uhlig, Rikke Helene, Moe, Maarten, de Wit, Argjend, Tafaj, Vahan, Mukuchyan, Paul, Studenic, Patrick, Verschueren, Russka, Shumnalieva, Paraskevi, Charalambous, Jiří, Vencovský, Melpomeni, Varvouni, Mart, Kull, Kari, Puolakka, Laure, Gossec, Nino, Gobejishvili, Jacqueline, Detert, Prodromos, Sidiropoulos, Márta, Péntek, David, Kane, Carlo Alberto, Scirè, Uri, Arad, Daina, Andersone, Mart, van de Laar, Annette, van der Helm-van Mil, Piotr, Głuszko, Luís, Cunha-Miranda, Florian, Berghea, Nemanja S, Damjanov, Matija, Tomšič, Loreto, Carmona, Carl, Turesson, Adrian, Ciurea, Surayo, Shukurova, Nevsun, Inanc, Suzanne Mm, Verstappen, Annelies, Boonen, Edi, Rembeci, Meisters, R, Putrik, P, Ramiro, S, Hifinger, M, Keszei, A, Van Eijk-Hustings, Y, Woolf, A, Smolen, J, Stamm, T, Stoffer-Marx, M, Uhlig, T, Moe, R, De Wit, M, Tafaj, A, Mukuchyan, V, Studenic, P, Verschueren, P, Shumnalieva, R, Charalambous, P, Vencovsky, J, Varvouni, M, Kull, M, Puolakka, K, Gossec, L, Gobejishvili, N, Detert, J, Sidiropoulos, P, Pentek, M, Kane, D, Scire, C, Arad, U, Andersone, D, Van De Laar, M, Van Der Helm-Van Mil, A, Gluszko, P, Cunha-Miranda, L, Berghea, F, Damjanov, N, Tomsic, M, Carmona, L, Turesson, C, Ciurea, A, Shukurova, S, Inanc, N, Verstappen, S, Boonen, A, Health Services Research, RS: CAPHRI - R2 - Creating Value-Based Health Care, RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, Health promotion, Interne Geneeskunde, MUMC+: KIO Kemta (9), MUMC+: MA Reumatologie (9), and Psychology, Health & Technology
- Subjects
Adult ,Male ,medicine.medical_specialty ,arthritis, health services research, health care, outcome and process assessment, Rheumatology, Standard of Care ,rheumatoid ,Immunology ,Arthritis ,General Biochemistry, Genetics and Molecular Biology ,Gross domestic product ,NO ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Surveys and Questionnaires ,Health care ,medicine ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,Registries ,GUIDELINE DISSEMINATION ,Aged ,030203 arthritis & rheumatology ,business.industry ,Health services research ,Standard of Care ,Middle Aged ,medicine.disease ,outcome and process assessment ,health care ,n/a OA procedure ,health services research ,Multilevel logistic regression ,Europe ,arthriti ,Cross-Sectional Studies ,arthritis ,Rheumatoid arthritis ,Family medicine ,Female ,HEALTH ,Rheumatologists ,business ,Rheumatism - Abstract
ObjectiveAs part of European League against Rheumatism (EULAR)/European Musculoskeletal Conditions Surveillance and Information Network, 20 user-focused standards of care (SoCs) for rheumatoid arthritis (RA) addressing 16 domains of care were developed. This study aimed to explore gaps in implementation of these SoCs across Europe.MethodsTwo cross-sectional surveys on the importance, level of and barriers (patients only) to implementation of each SoC (0–10, 10 highest) were designed to be conducted among patients and rheumatologists in 50 European countries. Care gaps were calculated as the difference between the actual and maximum possible score for implementation (ie, 10) multiplied by the care importance score, resulting in care gaps (0–100, maximal gap). Factors associated with the problematic care gaps (ie, gap≥30 and importance≥6 and implementationResultsOverall, 26 and 31 countries provided data from 1873 patients and 1131 rheumatologists, respectively. 19 out of 20 SoCs were problematic from the perspectives of more than 20% of patients, while this was true for only 10 SoCs for rheumatologists. Rheumatologists in countries with lower gross domestic product and non-European Union countries were more likely to report problematic gaps in 15 of 20 SoCs, while virtually no differences were observed among patients. Lack of relevance of some SoCs (71%) and limited time of professionals (66%) were the most frequent implementation barriers identified by patients.ConclusionsMany problematic gaps were reported across several essential aspects of RA care. More efforts need to be devoted to implementation of EULAR SoCs.
- Published
- 2020
- Full Text
- View/download PDF
239. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort
- Author
-
Muriel Elhai, Nanthara Sritharan, Marouane Boubaya, Alexandra Balbir-Gurman, Elise Siegert, Eric Hachulla, Jeska de Vries-Bouwstra, Gabriela Riemekasten, Jörg H W Distler, Edoardo Rosato, Francesco Del Galdo, Fabian A Mendoza, Daniel E Furst, Carlos de la Puente, Anna-Maria Hoffmann-Vold, Armando Gabrielli, Oliver Distler, Coralie Bloch-Queyrat, Yannick Allanore, Marco Matucci Cerinic, Ulrich Walker, Florenzo Iannone, Suzana Jordan, Radim Becvar, Otylia Kowal Bielecka, Maurizio Cutolo, Giovanna Cuomo, Claudia Kedor, Simona Rednic, Jérome Avouac, P. Vlachoyiannopoulos, C. Montecucco, Jiri Stork, Murat Inanc, Patricia E. Carreira, Srdan Novak, László Czirják, Michele Iudici, Eugene J. Kucharz, Elisabetta Zanatta, Katja Perdan-Pirkmajer, Bernard Coleiro, Gianluca Moroncini, Dominique Farge Bancel, Paolo Airò, Roger Hesselstrand, Mislav Radic, Yolanda Braun-Moscovici, Andrea Lo Monaco, Nicolas Hunzelmann, Raffaele Pellerito, Alessandro Giollo, Jadranka Morovic-Vergles, Christopher Denton, Madelon Vonk, Nemanja Damjanov, Jörg Henes, Vera Ortiz Santamaria, Stefan Heitmann, Dorota Krasowska, Paul Hasler, Michaela Kohm, Ivan Foeldvari, Gianluigi Bajocchi, Maria João Salvador, Bojana Stamenkovic, Carlo Francesco Selmi, Mohammed Tikly, Lidia P. Ananieva, Ariane Herrick, Ulf Müller-Ladner, Raffaele De Palma, Merete Engelhart, Gabriela Szücs, Cristina Sobrino Grande, Øyvind Midtvedt, David Launay, Valeria Riccieri, Ruxandra Maria Ionescu, Ami Sha, Ana Maria Gheorghiu, Cord Sunderkötter, Francesca Ingegnoli, Luc Mouthon, Vanessa Smith, Francesco Paolo Cantatore, Susanne Ullman, Carlos Alberto von Mühlen, Maria Rosa Pozzi, Kilian Eyerich, Piotr Wiland, Marie Vanthuyne, Juan Jose Alegre-Sancho, Kristine Herrmann, Ellen De Langhe, Branimir Anic, Maria Üprus, Sule Yavuz, Brigitte Granel, Carolina de Souza Müller, Joanna Busquets, Svetlana Agachi, Simon Stebbings, D'Alessandro Mathieu, Percival D. Sampaio-Barros, Lisa Stamp, Kamal Solanki, Douglas Veale, Esthela Loyo, Mengtao Li, Walid Ahmed Abdel Atty Mohamed, Antonietta Gigante, Fahrettin Oksel, Cristina-Mihaela Tanaseanu, Rosario Foti, Codrina Ancuta, Britta Maurer, Jacob van Laar, Cristiane Kayser, Nihal Fathi, Paloma García de la Peña Lefebvre, Jean Sibilia, Ira Litinsky, Giuseppina Abignano, Goda Seskute, Lesley Ann Saketkoo, Eduardo Kerzberg, Washington Bianchi, Ivan Castellví, Massimiliano Limonta, Doron Rimar, Maura Couto, François Spertini, Antonella Marcoccia, Sarah Kahl, Ivien M. Hsu, Thierry Martin, Sergey Moiseev, Lorinda S. Chung, Tim Schmeiser, Dominik Majewski, Zbigniew Zdrojewski, Julia Martínez-Barrio, Vera Bernardino, Sabine Sommerlatte, Yair Levy, Elena Rezus, Omer Nuri Pamuk, Piercarlo Sarzi Puttini, Hadi Poormoghim, Ina Kötter, Francis Gaches, Laura Belloli, Petros Sfikakis, Juliana Markus, Gary R Feldman, Ana-Maria Ramazan, H.U. Scherer, Marie-Elise Truchetet, Alain Lescoat, Lorenzo Dagna, J.M. van Laar, Lidia Rudnicka, Susana Oliveira, Fabiola Atzeni, Masataka Kuwana, Arsene Mekinian, Mickaël Martin, Yoshiya Tanaka, Elhai, M., Sritharan, N., Boubaya, M., Balbir-Gurman, A., Siegert, E., Hachulla, E., de Vries-Bouwstra, J., Riemekasten, G., Distler, J. H. W., Rosato, E., Del Galdo, F., Mendoza, F. A., Furst, D. E., de la Puente, C., Hoffmann-Vold, A. -M., Gabrielli, A., Distler, O., Bloch-Queyrat, C., Allanore, Y., Matucci Cerinic, M., Walker, U., Iannone, F., Jordan, S., Becvar, R., Kowal Bielecka, O., Cutolo, M., Cuomo, G., Kedor, C., Rednic, S., Avouac, J., Vlachoyiannopoulos, P., Montecucco, C., Stork, J., Inanc, M., Carreira, P. E., Novak, S., Czirjak, L., Iudici, M., Kucharz, E. J., Zanatta, E., Perdan-Pirkmajer, K., Coleiro, B., Moroncini, G., Farge Bancel, D., Airo, P., Hesselstrand, R., Radic, M., Braun-Moscovici, Y., Lo Monaco, A., Hunzelmann, N., Pellerito, R., Giollo, A., Morovic-Vergles, J., Denton, C., Vonk, M., Damjanov, N., Henes, J., Ortiz Santamaria, V., Heitmann, S., Krasowska, D., Hasler, P., Kohm, M., Foeldvari, I., Bajocchi, G., Salvador, M. J., Stamenkovic, B., Selmi, C. F., Tikly, M., Ananieva, L. P., Herrick, A., Muller-Ladner, U., De Palma, R., Engelhart, M., Szucs, G., Sobrino Grande, C., Midtvedt, O., Launay, D., Riccieri, V., Ionescu, R. M., Sha, A., Gheorghiu, A. M., Sunderkotter, C., Ingegnoli, F., Mouthon, L., Smith, V., Cantatore, F. P., Ullman, S., Alberto von Muhlen, C., Pozzi, M. R., Eyerich, K., Wiland, P., Vanthuyne, M., Alegre-Sancho, J. J., Herrmann, K., De Langhe, E., Anic, B., Uprus, M., Yavuz, S., Granel, B., de Souza Muller, C., Busquets, J., Agachi, S., Stebbings, S., Mathieu, D. A., Sampaio-Barros, P. D., Stamp, L., Solanki, K., Veale, D., Loyo, E., Li, M., Abdel Atty Mohamed, W. A., Gigante, A., Oksel, F., Tanaseanu, C. -M., Foti, R., Ancuta, C., Maurer, B., van Laar, J., Kayser, C., Fathi, N., Garcia de la Pena Lefebvre, P., Sibilia, J., Litinsky, I., Abignano, G., Seskute, G., Saketkoo, L. A., Kerzberg, E., Bianchi, W., Castellvi, I., Limonta, M., Rimar, D., Couto, M., Spertini, F., Marcoccia, A., Kahl, S., Hsu, I. M., Martin, T., Moiseev, S., Chung, L. S., Schmeiser, T., Majewski, D., Zdrojewski, Z., Martinez-Barrio, J., Bernardino, V., Sommerlatte, S., Levy, Y., Rezus, E., Nuri Pamuk, O., Sarzi Puttini, P., Poormoghim, H., Kotter, I., Gaches, F., Belloli, L., Sfikakis, P., Markus, J., Feldman, G. R., Ramazan, A. -M., Scherer, H. U., Truchetet, M. -E., Lescoat, A., Dagna, L., van Laar, J. M., Rudnicka, L., Oliveira, S., Atzeni, F., Kuwana, M., Mekinian, A., Martin, M., and Tanaka, Y.
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy - Abstract
Background: The current subclassification of systemic sclerosis into cutaneous subtypes does not fully capture the heterogeneity of the disease. We aimed to compare the performances of stratification into LeRoy's cutaneous subtypes versus stratification by autoantibody status in systemic sclerosis. Methods: For this cohort study, we assessed people with systemic sclerosis in the multicentre international European Scleroderma Trials and Research (EUSTAR) database. Individuals positive for systemic-sclerosis autoantibodies of two specificities were excluded, and remaining individuals were classified by cutaneous subtype, according to their systemic sclerosis-specific autoantibodies, or both. We assessed the performance of each model to predict overall survival, progression-free survival, disease progression, and different organ involvement. The three models were compared by use of the area under the curve (AUC) of the receiver operating characteristic and the net reclassification improvement (NRI). Missing data were imputed. Findings: We assessed the database on July 26, 2019. Of 16 939 patients assessed for eligibility, 10 711 patients were included: 1647 (15·4%) of 10 709 were male, 9062 (84·6%) were female, mean age was 54·4 (SD 13·8) years, and mean disease duration was 7·9 (SD 8·2) years. Information regarding cutaneous subtype was available for 10 176 participants and antibody data were available for 9643 participants. In the prognostic analysis, there was no difference in AUC for overall survival (0·82, 95% CI 0·81–0·84 for cutaneous only vs 0·84, 0·82–0·85 for antibody only vs 0·84, 0·83–0·86 for combined) or for progression-free survival (0·70, 0·69–0·71 vs 0·71, 0·70–0·72 vs 0·71, 0·70–0·72). However, at 4 years the NRI showed substantial improvement for the antibody-only model compared with the cutaneous-only model in prediction of overall survival (0·57, 0·46–0·71 for antibody only vs 0·29, 0·19–0·39 for cutaneous only) and disease progression (0·36, 0·29–0·46 vs 0·21, 0·14–0·28). The antibody-only model did better than the cutaneous-only model in predicting renal crisis (AUC 0·72, 0·70–0·74 for antibody only vs 0·66, 0·64–0·69 for cutaneous only) and lung fibrosis leading to restrictive lung function (AUC 0·76, 0·75–0·77 vs 0·71, 0·70–0·72). The combined model improved the prediction of digital ulcers and elevated systolic pulmonary artery pressure, but did poorly for cardiac involvement. Interpretation: The autoantibody-only model outperforms cutaneous-only subsetting for risk stratifying people with systemic sclerosis in the EUSTAR cohort. Physicians should be aware of these findings at the time of decision making for patient management. Funding: World Scleroderma Foundation.
- Published
- 2022
240. Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study
- Author
-
Christel Madelaine Bonjour, Carlos Pineda, Florentin Ananu Vreju, Dario Gambera, Raquel Largo, Leonardo Punzi, Pascal Zufferey, Gabriel Herrero-Beaumont, Lene Terslev, Héctor Iván García, Daryl K. MacCarter, Stanley Makman, F. Figus, C. Toscano, Annamaria Iagnocco, Antonella Adinolfi, Victor Ilizaliturri, Ingrid Möller, D.C. Grecu, Emilio Filippucci, Anna Scanu, George A W Bruyn, Teodora Serban, Helen Keen, Catalin Cirstoiu, Gaël Mouterde, Maria Antonietta D'Agostino, Zachary Weber, Edoardo Cipolletta, Emilio Calvo, Jaime Mendoza Torres, Raul Pichardo, Marcello Govoni, Carlo Alberto Scirè, Luis Carlos Rodriguez Delgado, Marwin Gutierrez, Denise Clavijo Cornejo, Georgios Filippou, Nemanja Damjanov, Esperanza Naredo, Filippou, G, Scanu, A, Adinolfi, A, Toscano, C, Gambera, D, Largo, R, Naredo, E, Calvo, E, Herrero-Beaumont, G, Zufferey, P, Bonjour, C, Maccarter, D, Makman, S, Weber, Z, Figus, F, Moller, I, Gutierrez, M, Pineda, C, Clavijo Cornejo, D, Garcia, H, Ilizaliturri, V, Mendoza Torres, J, Pichardo, R, Rodriguez Delgado, L, Filippucci, E, Cipolletta, E, Serban, T, Cirstoiu, C, Vreju, F, Grecu, D, Mouterde, G, Govoni, M, Punzi, L, Damjanov, N, Keen, H, Bruyn, G, Terslev, L, D'Agostino, M, Scire, C, and Iagnocco, A
- Subjects
Male ,Settore MED/16 - REUMATOLOGIA ,chondrocalcinosis ,knee ,osteoarthritis ,ultrasonography ,Aged ,Arthroplasty, Replacement, Knee ,Calcium Pyrophosphate ,Chondrocalcinosis ,Female ,Humans ,Hyaline Cartilage ,Meniscus ,Microscopy ,Middle Aged ,Osteoarthritis, Knee ,Preoperative Period ,Reference Values ,Reproducibility of Results ,Sensitivity and Specificity ,Ultrasonography ,medicine.medical_treatment ,Replacement ,Knee replacement ,Osteoarthritis ,Meniscus (anatomy) ,chemistry.chemical_compound ,Immunology and Allergy ,Hyaline cartilage ,Ultrasound ,Calcium pyrophosphate ,medicine.anatomical_structure ,osteoarthriti ,Medial meniscus ,musculoskeletal diseases ,Immunology ,General Biochemistry, Genetics and Molecular Biology ,Arthroplasty ,NO ,Rheumatology ,chondrocalcinosi ,medicine ,business.industry ,medicine.disease ,chemistry ,Nuclear medicine ,business - Abstract
ObjectiveTo evaluate the discriminatory ability of ultrasound in calcium pyrophosphate deposition disease (CPPD), using microscopic analysis of menisci and knee hyaline cartilage (HC) as reference standard.MethodsConsecutive patients scheduled for knee replacement surgery, due to osteoarthritis (OA), were enrolled. Each patient underwent ultrasound examination of the menisci and HC of the knee, scoring each site for presence/absence of CPPD. Ultrasound signs of inflammation (effusion, synovial proliferation and power Doppler) were assessed semiquantitatively (0–3). The menisci and condyles, retrieved during surgery, were examined microscopically by optical light microscopy and by compensated polarised microscopy. CPPs were scored as present/absent in six different samples from the surface and from the internal part of menisci and cartilage. Ultrasound and microscopic analysis were performed by different operators, blinded to each other’s findings.Results11 researchers from seven countries participated in the study. Of 101 enrolled patients, 68 were included in the analysis. In 38 patients, the surgical specimens were insufficient. The overall diagnostic accuracy of ultrasound for CPPD was of 75%—sensitivity of 91% (range 71%–87% in single sites) and specificity of 59% (range 68%–92%). The best sensitivity and specificity were obtained by assessing in combination by ultrasound the medial meniscus and the medial condyle HC (88% and 76%, respectively). No differences were found between patients with and without CPPD regarding ultrasound signs of inflammation.ConclusionUltrasound demonstrated to be an accurate tool for discriminating CPPD. No differences were found between patents with OA alone and CPPD plus OA regarding inflammation.
- Published
- 2021
241. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management
- Author
-
Mengtao Li, Xiaofeng Zeng, Thomas Krieg, Yukai Wang, Marco Matucci-Cerinic, Daniel E. Furst, Nemanja Damjanov, Yannick Allanore, Lorenzo Dagna, Dinesh Khanna, Eun Bong Lee, Gloria Taliani, David A. Fox, Christopher P. Denton, Masataka Kuwana, Oliver Distler, Amato de Paulis, Cosimo Bruni, Shiv Pillai, Massimo Clementi, Matucci-Cerinic, M., Bruni, C., Allanore, Y., Clementi, M., Dagna, L., Damjanov, N. S., De Paulis, A., Denton, C. P., Distler, O., Fox, D., Furst, D. E., Khanna, D., Krieg, T., Kuwana, M., Lee, E. B., Li, M., Pillai, S., Wang, Y., Zeng, X., Taliani, G., University of Zurich, and Matucci-Cerinic, Marco
- Subjects
2745 Rheumatology ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Scleroderma ,Immunosuppressive Agent ,0302 clinical medicine ,Pandemic ,Immunology and Allergy ,scleroderma ,skin and connective tissue diseases ,COVID ,Coronavirus ,Respiratory Distress Syndrome ,10051 Rheumatology Clinic and Institute of Physical Medicine ,Interstitial lung disease ,Foundation (evidence) ,3. Good health ,2723 Immunology and Allergy ,Coronavirus Infections ,Immunosuppressive Agents ,medicine.drug ,Human ,medicine.medical_specialty ,hydroxychloroquine ,Coronavirus disease 2019 (COVID-19) ,Immunology ,Pneumonia, Viral ,610 Medicine & health ,autoimmune disease ,Antibodies, Monoclonal, Humanized ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Betacoronavirus ,Rheumatology ,1300 General Biochemistry, Genetics and Molecular Biology ,Internal medicine ,medicine ,Humans ,Intensive care medicine ,Pandemics ,030203 arthritis & rheumatology ,2403 Immunology ,Scleroderma, Systemic ,Betacoronaviru ,business.industry ,Coronavirus Infection ,SARS-CoV-2 ,COVID-19 ,Hydroxychloroquine ,systemic ,medicine.disease ,business ,Lung Diseases, Interstitial - Abstract
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
- Published
- 2020
242. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort
- Author
-
Wu, Wanlong, Jordan, Suzana, Graf, Nicole, Pena, Janethe de Oliveira, Curram, John, Allanore, Yannick, Matucci-Cerinic, Marco, Pope, Janet E., Denton, Christopher P., Khanna, Dinesh, Distler, Oliver, Guiducci, Serena, Walker, Ulrich, Jaeger, Veronika, Bannert, Bettina, Lapadula, Giovanni, Becvarare, Radim, Cutolo, Maurizio, Valentini, Gabriele, Siegert, Elise, Rednic, Simona, Montecucco, C., Carreira, Patricia E., Novak, Srdan, Czirjak, Laszlo, Varju, Cecilia, Chizzolini, Carlo, Allai, Daniela, Kucharz, Eugene J., Cozzi, Franco, Rozman, Blaz, Mallia, Carmel, Gabrielli, Armando, Bancel, Dominique Farge, Airo, Paolo, Hesselstrand, Roger, Martinovic, Duska, Balbir-Gurman, Alexandra, Braun-Moscovici, Yolanda, Hunzelmann, Nicolas, Pellerito, Raffaele, Caramaschi, Paola, Black, Carol, Damjanov, Nemanja, Henes, Joerg, Ortiz Santamaria, Vera, Heitmann, Stefan, Seidel, Matthias, Pereira Da Silva, Jose Antonio, Stamenkovic, Bojana, Selmi, Carlo Francesco, Tikly, Mohammed, Denisov, Lev N., Mueller-Ladner, Ulf, Engelhart, Merete, Hachulla, Eric, Riccieri, Valeria, Ionescu, Ruxandra Maria, Mihai, Carina, Sunderkoetter, Cord, Kuhn, Annegret, Schett, Georg, Distler, Joerg, Meroni, Pierluigi, Ingegnoli, Francesca, Mouthon, Luc, De Keyser, Filip, Smith, Vanessa, Cantatore, Francesco Paolo, Corrado, Ada, Ullman, Susanne, Iversen, Line, Pozzi, Maria Rosa, Eyerich, Kilian, Hein, Ruediger, Knott, Elisabeth, Wiland, Piotr, Szmyrka-Kaczmarek, Magdalena, Sokolik, Renata, Morgiel, Ewa, Madej, Marta, Jose Alegre-Sancho, Juan, Krummel-Lorenz, Brigitte, Saar, Petra, Aringer, Martin, Guenther, Claudia, Anne, Erler, Westhovens, Rene, De Langhe, Ellen, Lenaerts, Jan, Anic, Branimir, Baresic, Marko, Mayer, Miroslav, Uprus, Maria, Otsa, Kati, Yavuz, Sule, Radominski, Sebastiao Cezar, Mueller, Carolina de Souza, Azevedo, Valderilio Feijo, Popa, Sergei, Zenone, Thierry, Stebbings, Simon, Highton, John, Mathieu, Alessandro, Vacca, Alessandra, Stamp, Lisa, Chapman, Peter, O'Donnell, John, Solanki, Kamal, Doube, Alan, Veale, Douglas, O'Rourke, Marie, Loyo, Esthela, Li, Mengtao, Rosato, Edoardo, Amoroso, Antonio, Gigante, Antonietta, Oksel, Fahrettin, Yargucu, Figen, Tanaseanu, Cristina-Mihaela, Popescu, Monica, Dumitrascu, Alina, Tiglea, Isabela, Foti, Rosario, Visalli, Elisa, Benenati, Alessia, Amato, Giorgio, Ancuta, Codrina, Chirieac, Rodica, Villiger, Peter, Adler, Sabine, Dan, Diana, de la Pena Lefebvre, Paloma Garcia, Rodriguez Rubio, Silvia, Valero Exposito, Marta, Sibilia, Jean, Chatelus, Emmanuel, Gottenberg, Jacques Eric, Chifflot, Helene, Litinsky, Ira, Del Galdo, Francesco, Venalis, Algirdas, Saketkoo, Lesley Ann, Lasky, Joseph A., Kerzberg, Eduardo, Montoya, Fabiana, Cosentino, Vanesa, Limonta, Massimiliano, Brucato, Antonio Luca, Lupi, Elide, Spertini, Francois, Ribi, Camillo, Buss, Guillaume, Martin, Thierry, Guffroy, Aurelien, Poindron, Vincent, Chung, Lori, Schmeiser, Tim, Zebryk, Pawel, Riso, Nuno, Riemekasten, Gabriela, Rezus, Elena, Puttini, Piercarlo Sarzi, Wu, W., Jordan, S., Graf, N., de Oliveira Pena, J., Curram, J., Allanore, Y., Matucci-Cerinic, M., Pope, J. E., Denton, C. P., Khanna, D., Distler, O., Guiducci, S., Walker, U., Jaeger, V., Bannert, B., Lapadula, G., Becvarare, R., Cutolo, M., Valentini, G., Siegert, E., Rednic, S., Montecucco, C., Carreira, P. E., Novak, S., Czirjak, L., Varju, C., Chizzolini, C., Allai, D., Kucharz, E. J., Cozzi, F., Rozman, B., Mallia, C., Gabrielli, A., Bancel, D. F., Airo, P., Hesselstrand, R., Martinovic, D., Balbir-Gurman, A., Braun-Moscovici, Y., Hunzelmann, N., Pellerito, R., Caramaschi, P., Black, C., Damjanov, N., Henes, J., Santamaria, V. O., Heitmann, S., Seidel, M., Pereira Da Silva, J. A., Stamenkovic, B., Selmi, C. F., Tikly, M., Denisov, L. N., Muller-Ladner, U., Engelhart, M., Hachulla, E., Riccieri, V., Ionescu, R. M., Mihai, C., Sunderkotter, C., Kuhn, A., Schett, G., Distler, J., Meroni, P., Ingegnoli, F., Mouthon, L., De Keyser, F., Smith, V., Cantatore, F. P., Corrado, A., Ullman, S., Iversen, L., Pozzi, M. R., Eyerich, K., Hein, R., Knott, E., Wiland, P., Szmyrka-Kaczmarek, M., Sokolik, R., Morgiel, E., Madej, M., Alegre-Sancho, J. J., Krummel-Lorenz, B., Saar, P., Aringer, M., Gunther, C., Anne, E., Westhovens, R., De Langhe, E., Lenaerts, J., Anic, B., Baresic, M., Mayer, M., Uprus, M., Otsa, K., Yavuz, S., Radominski, S. C., de Souza Muller, C., Azevedo, V. F., Popa, S., Zenone, T., Stebbings, S., Highton, J., Mathieu, A., Vacca, A., Stamp, L., Chapman, P., O'Donnell, J., Solanki, K., Doube, A., Veale, D., O'Rourke, M., Loyo, E., Li, M., Rosato, E., Amoroso, A., Gigante, A., Oksel, F., Yargucu, F., Tanaseanu, C. -M., Popescu, M., Dumitrascu, A., Tiglea, I., Foti, R., Visalli, E., Benenati, A., Amato, G., Ancuta, C., Chirieac, R., Villiger, P., Adler, S., Dan, D., de la Pena Lefebvre, P. G., Rubio, S. R., Exposito, M. V., Sibilia, J., Chatelus, E., Gottenberg, J. E., Chifflot, H., Litinsky, I., Del Galdo, F., Venalis, A., Saketkoo, L. A., Lasky, J. A., Kerzberg, E., Montoya, F., Cosentino, V., Limonta, M., Brucato, A. L., Lupi, E., Spertini, F., Ribi, C., Buss, G., Martin, T., Guffroy, A., Poindron, V., Chung, L., Schmeiser, T., Zebryk, P., Riso, N., Riemekasten, G., Rezus, E., Sarzi Puttini, P., Ege Üniversitesi, Chizzolini, Carlo, Allali, Danièle, University of Zurich, and Distler, Oliver
- Subjects
INVOLVEMENT ,Male ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences ,diffuse ,Time Factors ,Databases, Factual ,Skin Diseases/etiology/mortality/physiopathology ,PREDICTION ,Fibrosi ,2745 Rheumatology ,Diffuse/complications/mortality/pathology ,Immunology ,General Biochemistry, Genetics and Molecular Biology ,Immunology and Allergy ,Rheumatology ,Kaplan-Meier Estimate ,ddc:616.07 ,Severity of Illness Index ,Scleroderma ,Cohort Studies ,PROGNOSTIC-FACTORS ,Fibrosis ,Medicine and Health Sciences ,scleroderma ,Lung ,Skin ,integumentary system ,progressive skin fibrosis ,Lung function decline ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti ,10051 Rheumatology Clinic and Institute of Physical Medicine ,DEATH ,Middle Aged ,ddc ,Europe ,VARIABILITY ,factual ,Cohort ,Visceral organ progression ,2723 Immunology and Allergy ,Disease Progression ,Female ,Survival Analysi ,Life Sciences & Biomedicine ,Cohort study ,Human ,Adult ,Skin/pathology ,medicine.medical_specialty ,databases ,All-cause death ,risk analysis ,diffuse cutaneous systemic sclerosis ,610 Medicine & health ,IMPROVEMENT ,Systemic Sclerosis ,Skin Diseases ,THICKNESS SCORE ,VALIDATION ,Databases ,FEV1/FVC ratio ,1300 General Biochemistry, Genetics and Molecular Biology ,Internal medicine ,medicine ,Humans ,Factual ,Survival analysis ,2403 Immunology ,Science & Technology ,Proportional hazards model ,business.industry ,Surrogate endpoint ,MORTALITY ,Skin Disease ,fibrosis ,Progressive skin fibrosi ,Lung/physiopathology ,biomarkers ,Diffuse cutaneous systemic sclerosi ,medicine.disease ,Survival Analysis ,all-cause death ,lung function decline ,visceral organ progression ,adult ,cohort studies ,databases, factual ,disease progression ,female ,humans ,Scleroderma, Diffuse ,Cohort Studie ,business - Abstract
PubMed: 30852552, Objectives To determine whether progressive skin fibrosis is associated with visceral organ progression and mortality during follow-up in patients with diffuse cutaneous systemic sclerosis (dcSSc). Methods We evaluated patients from the European Scleroderma Trials and Research database with dcSSc, baseline modified Rodnan skin score (mRSS) ?7, valid mRSS at 12±3 months after baseline and ?1 annual follow-up visit. Progressive skin fibrosis was defined as an increase in mRSS >5 and ?25% from baseline to 12±3 months. Outcomes were pulmonary, cardiovascular and renal progression, and all-cause death. Associations between skin progression and outcomes were evaluated by Kaplan-Meier survival analysis and multivariable Cox regression. Results Of 1021 included patients, 78 (7.6%) had progressive skin fibrosis (skin progressors). Median follow-up was 3.4 years. Survival analyses indicated that skin progressors had a significantly higher probability of FVC decline ?10% (53.6% vs 34.4%; p, Bayer Bayer, 1Department of Rheumatology, University Hospital Zurich, Zurich, switzerland 2Graf Biostatistics, Winterthur, switzerland 3Clinical Development Pulmonology, Bayer Us llC, Whippany, new Jersey, Usa 4Data science and analytics, Bayer plc, Reading, UK 5Rheumatology a Department, Paris Descartes University, inseRM U1016, sorbonne, Paris Cité, Cochin Hospital, Paris, France 6Division of Rheumatology, University of Florence, Florence, italy 7Department of Medicine, Division of Rheumatology, University of Western Ontario, st. Joseph’s Health Care, london, Western Ontario, Canada 8Department of Rheumatology, Royal Free Hospital, University College london, london, UK 9scleroderma Program, Department of internal Medicine, Division of Rheumatology, University of Michigan, ann arbor, Michigan, Usa Acknowledgements The authors thank nicole schneider for excellent administration and data entry into the eUsTaR cohort. Medical writing assistance was provided by adelphi Communications ltd (Bollington, UK), funded by Bayer aG (Berlin, Germany)., This study was supported by a grant from Bayer aG.
- Published
- 2019
243. Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis
- Author
-
Sobanski, Vincent, Giovannelli, Jonathan, Allanore, Yannick, Riemekasten, Gabriela, Airo, Paolo, Vettori, Serena, Cozzi, Franco, Distler, Oliver, Matucci-Cerinic, Marco, Denton, Christopher, Launay, David, Hachulla, Eric, Cerinic, Marco Matucci, Guiducci, Serena, Walker, Ulrich, Kyburz, Diego, Lapadula, Giovanni, Iannone, Florenzo, Maurer, Britta, Jordan, Suzana, Becvar, Radim, Sierakowsky, Stanislaw, Bielecka, Otylia Kowal, Cutolo, Maurizio, Sulli, Alberto, Valentini, Gabriele, Cuomo, Giovanna, Siegert, Elise, Rednic, Simona, Nicoara, Ileana, Kahan, Andre, Vlachoyiannopoulos, Panayiotis, Montecucco, Carlo, Caporali, Roberto, Stork, Jiri, Inanc, Murat, Carreira, Patricia E, Novak, Srdan, Czirjak, Laszlo, Varju, Cecilia, Chizzolini, Carlo, Kucharz, Eugene J, Kotulska, Anna, Kopec-Medrek, Magdalena, Widuchowska, Malgorzata, Rozman, Blaz, Mallia, Carmel, Coleiro, Bernard, Gabrielli, Armando, Farge, Dominique, Wu, Chen, Marjanovic, Zora, Faivre, Helene, Hij, Darin, Dhamadi, Roza, Hesselstrand, Roger, Wollheim, Frank, Wuttge, Dirk M, Andreasson, Kristofer, Martinovic, Duska, Balbir-Gurman, Alexandra, Braun-Moscovici, Yolanda, Trotta, Francesco, Lo Monaco, Andrea, Hunzelmann, Nicolas, Pellerito, Raffaele, Bambara, Lisa Maria, Caramaschi, Paola, Morovic-Vergles, Jadranka, Black, Carol, Damjanov, Nemanja, Henes, Joerg, Ortiz Santamaria, Vera, Heitmann, Stefan, Krasowska, Dorota, Seidel, Matthias, Hasler, Paul, Burkhardt, Harald, Himsel, Andrea, Bajocchi, Gianluigi, Nuova, Arcispedale Santa Maria, Salvador, Maria Joao, Pereira Da Silva, Jose Antonio, Stamenkovic, Bojana, Stankovic, Aleksandra, Selmi, Carlo Francesco, De Santis, Maria, Marasini, Bianca, Tikly, Mohammed, Ananieva, Lidia P, Denisov, Lev N, Mueller-Ladner, Ulf, Frerix, Marc, Tarner, Ingo, Scorza, Raffaella, Puppo, Francesco, Engelhart, Merete, Strauss, Gitte, Nielsen, Henrik, Damgaard, Kirsten, Szucs, Gabriella, Szamosi, Szilvia, Zea Mendoza, Antonio, de la Puente, Carlos, Sifuentes Giraldo, Walter Alberto, Midtvedt, Oyvind, Reiseter, Silje, Garen, Torhild, Valesini, Guido, Riccieri, Valeria, Ionescu, Ruxandra Maria, Opris, Daniela, Groseanu, Laura, Wigley, Fredrick M, Cornateanu, Roxana Sfrent, Ionitescu, Razvan, Gherghe, Ana Maria, Soare, Alina, Gorga, Marilena, Bojinca, Mihai, Mihai, Carina, Milicescu, Mihaela, Sunderkoetter, Cord, Kuhn, Annegret, Sandorfi, Nora, Schett, Georg, Distler, Joerg HW, Beyer, Christian, Meroni, Pierluigi, Ingegnoli, Francesca, Mouthon, Luc, De Keyser, Filip, Smith, Vanessa, Cantatore, Francesco Paolo, Corrado, Ada, Ullman, Susanne, Iversen, Line, von Muehlen, Carlos Alberto, Bohn, Jussara Marilu, Lonzetti, Lilian Scussel, Pozzi, Maria Rosa, Eyerich, Kilian, Hein, Ruediger, Knott, Elisabeth, Wiland, Piotr, Szmyrka-Kaczmarek, Magdalena, Sokolik, Renata, Morgiel, Ewa, Madej, Marta, Houssiau, Frederic A, Jose Alegre-Sancho, Juan, Krummel-Lorenz, Brigitte, Saar, Petra, Aringer, Martin, Guenther, Claudia, Westhovens, Rene, de Langhe, Ellen, Lenaerts, Jan, Anic, Branimir, Baresic, Marko, Mayer, Miroslav, Uprus, Maria, Otsa, Kati, Yavuz, Sule, Granel, Brigitte, Radominski, Sebastiao Cezar, Mueller, Carolina de Souza, Azevedo, Valderilio Feijo, Jimenez, Sergio, Busquets, Joanna, Agachi, Svetlana, Groppa, Liliana, Chiaburu, Lealea, Russu, Eugen, Popa, Sergei, Zenone, Thierry, Pileckyte, Margarita, Stebbings, Simon, Highton, John, Mathieu, Alessandro, Vacca, Alessandra, Sampaio-Barros, Percival D, Yoshinari, Natalino H, Marangoni, Roberta G, Martin, Patricia, Fuocco, Luiza, Stamp, Lisa, Chapman, Peter, O'Donnell, John, Solanki, Kamal, Doube, Alan, Veale, Douglas, O'Rourke, Marie, Loyo, Esthela, Li, Mengtao, Mohamed, Walid Ahmed Abdel Atty, Rosato, Edoardo, Amoroso, Antonio, Gigante, Antonietta, Oksel, Fahrettin, Yargucu, Figen, Tanaseanu, Cristina-Mihaela, Popescu, Monica, Dumitrascu, Alina, Tiglea, Isabela, Foti, Rosario, Chirieac, Rodica, Ancuta, Codrina, Furst, Daniel E, Villiger, Peter, Adler, Sabine, van Laar, Jacob, Kayser, Cristiane, Eduardo, Andrade Luis C, Fathi, Nihal, Hassanien, Manal, de la Pena Lefebvre, Paloma Garcia, Rodriguez Rubio, Silvia, Valero Exposito, Marta, Sibilia, Jean, Chatelus, Emmanuel, Gottenberg, Jacques Eric, Chifflot, Helene, Litinsky, Ira, Emery, Paul, Buch, Maya, Del Galdo, Francesco, Venalis, Algirdas, Butrimiene, Irena, Venalis, Paulius, Rugiene, Rita, Karpec, Diana, Saketkoo, Lesley Ann, Lasky, Joseph A, Kerzberg, Eduardo, Montoya, Fabiana, Cosentino, Vanesa, Limonta, Massimiliano, Brucato, Antonio Luca, Lupi, Elide, Rosner, Itzhak, Rozenbaum, Michael, Slobodin, Gleb, Boulman, Nina, Rimar, Doron, Couto, Maura, Spertini, Francois, Ribi, Camillo, Buss, Guillaume, Kahl, Sarah, Hsu, Vivien M, Chen, Fei, McCloskey, Deborah, Malveaux, Halina, Pasquali, Jean Louis, Martin, Thierry, Gorse, Audrey, Guffroy, Aurelien, Poindron, Vincent, EUSTAR Collaborators, Guiducci, S., Walker, U., Kyburz, D., Lapadula, G., Iannone, F., Maurer, B., Jordan, S., Becvar, R., Sierakowsky, S., Kowal Bielecka, O., Cutolo, M., Sulli, A., Valentini, G., Cuomo, G., Siegert, E., Rednic, S., Nicoara, I., Kahan, A., Vlachoyiannopoulos, P., Montecucco, C., Caporali, R., Stork, J., Inanc, M., Carreira, P.E., Novak, S., Czirják, L., Varju, C., Chizzolini, C., Kucharz, E.J., Kotulska, A., Kopec-Medrek, M., Widuchowska, M., Rozman, B., Mallia, C., Coleiro, B., Gabrielli, A., Farge, D., Wu, C., Marjanovic, Z., Faivre, H., Hij, D., Dhamadi, R., Airò, P., Hesselstrand, R., Wollheim, F., Wuttge, D.M., Andréasson, K., Martinovic, D., Balbir-Gurman, A., Braun-Moscovici, Y., Trotta, F., Lo Monaco, A., Hunzelmann, N., Pellerito, R., Mauriziano, O., Maria Bambara, L., Caramaschi, P., Morovic-Vergles, J., Black, C., Damjanov, N., Henes, J., Ortiz Santamaria, V., Heitmann, S., Krasowska, D., Seidel, M., Hasler, P., Burkhardt, H., Himsel, A., Bajocchi, G., Maria Nuova, A.S., João Salvador, M., Pereira Da Silva, J.A., Stamenkovic, B., Stankovic, A., Francesco Selmi, C., De Santis, M., Marasini, B., Tikly, M., Ananieva, L.P., Denisov, L.N., Müller-Ladner, U., Frerix, M., Tarner, I., Scorza, R., Puppo, F., Engelhart, M., Strauss, G., Nielsen, H., Damgaard, K., Szücs, G., Szamosi, S., Zea Mendoza, A., de la Puente, C., Sifuentes Giraldo, W.A., Midtvedt, Ø., Reiseter, S., Garen, T., Valesini, G., Riccieri, V., Maria Ionescu, R., Opris, D., Groseanu, L., Wigley, F.M., Sfrent Cornateanu, R., Ionitescu, R., Maria Gherghe, A., Soare, A., Gorga, M., Bojinca, M., Mihai, C., Milicescu, M., Sunderkötter, C., Kuhn, A., Sandorfi, N., Schett, G., Distler, J.H., Beyer, C., Meroni, P., Ingegnoli, F., Mouthon, L., De Keyser, F., Smith, V., Paolo Cantatore, F., Corrado, A., Ullman, S., Iversen, L., Alberto von Mühlen, C., Marilu Bohn, J., Scussel Lonzetti, L., Rosa Pozzi, M., Eyerich, K., Hein, R., Knott, E., Wiland, P., Szmyrka-Kaczmarek, M., Sokolik, R., Morgiel, E., Madej, M., Houssiau, F.A., Jose Alegre-Sancho, J., Krummel-Lorenz, B., Saar, P., Aringer, M., Günther, C., Westhovens, R., de Langhe, E., Lenaerts, J., Anic, B., Baresic, M., Mayer, M., Üprus, M., Otsa, K., Yavuz, S., Granel, B., Cezar Radominski, S., de Souza Müller, C., Azevedo, V.F., Jimenez, S., Busquets, J., Agachi, S., Groppa, L., Chiaburu, L., Russu, E., Popa, S., Zenone, T., Pileckyte, M., Stebbings, S., Highton, J., Mathieu, A., Vacca, A., Sampaio-Barros, P.D., Yoshinari, N.H., Marangoni, R.G., Martin, P., Fuocco, L., Stamp, L., Chapman, P., O'Donnell, J., Solanki, K., Doube, A., Veale, D., O'Rourke, M., Loyo, E., Li, M., Abdel Atty Mohamed, W.A., Rosato, E., Amoroso, A., Gigante, A., Oksel, F., Yargucu, F., Tanaseanu, C.M., Popescu, M., Dumitrascu, A., Tiglea, I., Foti, R., Chirieac, R., Ancuta, C., Furst, D.E., Villiger, P., Adler, S., van Laar, J., Kayser, C., Eduardo C, A.L., Fathi, N., Hassanien, M., de la Peña Lefebvre, P.G., Rodriguez Rubio, S., Valero Exposito, M., Sibilia, J., Chatelus, E., Gottenberg, J.E., Chifflot, H., Litinsky, I., Emery, P., Buch, M., Del Galdo, F., Venalis, A., Butrimiene, I., Venalis, P., Rugiene, R., Karpec, D., Ann Saketkoo, L., Lasky, J.A., Kerzberg, E., Montoya, F., Cosentino, V., Limonta, M., Luca Brucato, A., Lupi, E., Rosner, I., Rozenbaum, M., Slobodin, G., Boulman, N., Rimar, D., Couto, M., Spertini, F., Ribi, C., Buss, G., Kahl, S., Hsu, V.M., Chen, F., McCloskey, D., Malveaux, H., Louis Pasquali, J., Martin, T., Gorse, A., Guffroy, A., Poindron, V., and Chizzolini, Carlo
- Subjects
0301 basic medicine ,Male ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences ,Databases, Factual ,systemic sclerosis ,SUBSETS ,Disease ,Severity of Illness Index ,Scleroderma ,DISEASE ,0302 clinical medicine ,Medicine and Health Sciences ,Immunology and Allergy ,Cluster Analysis ,CRITERIA ,Prospective Studies ,Prospective cohort study ,skin and connective tissue diseases ,integumentary system ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti ,Adult ,Aged ,Autoantibodies/blood ,Europe/epidemiology ,Female ,Humans ,Middle Aged ,Phenotype ,Prognosis ,Scleroderma, Diffuse/blood ,Scleroderma, Diffuse/epidemiology ,Scleroderma, Diffuse/pathology ,Scleroderma, Limited/blood ,Scleroderma, Limited/epidemiology ,Scleroderma, Limited/pathology ,Scleroderma, Systemic/blood ,Scleroderma, Systemic/epidemiology ,Scleroderma, Systemic/pathology ,Connective tissue disease ,ddc ,Europe ,MANIFESTATIONS ,Cohort ,Life Sciences & Biomedicine ,medicine.medical_specialty ,Immunology ,PROFILE ,CLASSIFICATION ,03 medical and health sciences ,Rheumatology ,Scleroderma, Limited ,Internal medicine ,Severity of illness ,medicine ,Autoantibodies ,030203 arthritis & rheumatology ,Science & Technology ,Scleroderma, Systemic ,business.industry ,Autoantibody ,Systemic sclerosis (SSc) ,medicine.disease ,030104 developmental biology ,Scleroderma, Diffuse ,business - Abstract
OBJECTIVE: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involvement. This subclassification may not capture the entire variability of clinical phenotypes. The European Scleroderma Trials and Research (EUSTAR) database includes data on a prospective cohort of SSc patients from 122 European referral centers. This study was undertaken to perform a cluster analysis of EUSTAR data to distinguish and characterize homogeneous phenotypes without any a priori assumptions, and to examine survival among the clusters obtained. METHODS: A total of 11,318 patients were registered in the EUSTAR database, and 6,927 were included in the study. Twenty-four clinical and serologic variables were used for clustering. RESULTS: Clustering analyses provided a first delineation of 2 clusters showing moderate stability. In an exploratory attempt, we further characterized 6 homogeneous groups that differed with regard to their clinical features, autoantibody profile, and mortality. Some groups resembled usual dcSSc or lcSSc prototypes, but others exhibited unique features, such as a majority of lcSSc patients with a high rate of visceral damage and antitopoisomerase antibodies. Prognosis varied among groups and the presence of organ damage markedly impacted survival regardless of cutaneous involvement. CONCLUSION: Our findings suggest that restricting subsets of SSc patients to only those based on cutaneous involvement may not capture the complete heterogeneity of the disease. Organ damage and antibody profile should be taken into consideration when individuating homogeneous groups of patients with a distinct prognosis. ispartof: ARTHRITIS & RHEUMATOLOGY vol:71 issue:9 pages:1553-1570 ispartof: location:United States status: published
- Published
- 2019
244. OMERACT agreement and reliability study of ultrasonographic elementary lesions in osteoarthritis of the foot
- Author
-
Alen, Zabotti, Georgios, Filippou, Marco, Canzoni, Antonella, Adinolfi, Valentina, Picerno, Greta, Carrara, Peter, Balint, George A, Bruyn, Maria Antonietta, D'Agostino, Nemanja, Damjanov, Andrea, Delle Sedie, Emilio, Filippucci, Maria Luz, Gonzalez Fernandez, Hilde Berner, Hammer, Zunaid, Karim, Peter, Mandl, Ingrid, Moller, Maria Rosario, Morales Lozano, Esperanza, Naredo, Francesco, Porta, Garifallia, Sakellariou, Lene, Terslev, Carlo Alberto, Scirè, Annamaria, Iagnocco, Chiara, Scirocco, Zabotti, A, Filippou, G, Canzoni, M, Adinolfi, A, Picerno, V, Carrara, G, Balint, P, Bruyn, G, D'Agostino, M, Damjanov, N, Delle Sedie, A, Filippucci, E, Gonzalez Fernandez, M, Hammer, H, Karim, Z, Mandl, P, Moller, I, Morales Lozano, M, Naredo, E, Porta, F, Sakellariou, G, Terslev, L, Scire, C, and Iagnocco, A
- Subjects
Settore MED/16 - REUMATOLOGIA ,Immunology ,Osteoarthritis ,Severity of Illness Index ,Imaging ,NO ,outcomes research ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Reliability study ,Humans ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,Cartilage damage ,Reliability (statistics) ,Observer Variation ,030203 arthritis & rheumatology ,Foot ,business.industry ,Intraobserver reliability ,osteoarthritis, outcomes research, ultrasonography ,ultrasonography ,Joint effusion ,medicine.disease ,Exercise Therapy ,osteoarthritis ,Health Care Surveys ,osteoarthriti ,medicine.symptom ,business ,Nuclear medicine ,Kappa ,Foot (unit) - Abstract
ObjectiveTo evaluate the level of agreement on ultrasonographic (US) lesions among highly experienced sonographers as well as the intraobserver and interobserver reliability of inflammatory and structural US lesions in patients with osteoarthritis (OA) of the foot.MethodsAfter a systematic literature review, a Delphi survey was performed to test definitions of US lesions in OA of the foot, including inflammatory lesions (ie, synovial hypertrophy [SH], joint effusion [JE], power Doppler signal [PD]), and structural abnormalities (ie, cartilage damage [CD] and osteophytes). Subsequently, the reliability of US in assessing the aforementioned lesions was tested on static images as well as during a live exercise. Reliability was assessed by kappa analyses and prevalence-adjusted bias-adjusted kappa (PABAK) on a dichotomous and an ordinal scale.ResultsIntraobserver and interobserver reliability for SH and JE evaluated by binary scoring was good for both components, while the intraobserver reliability for semiquantitative scoring of SH ranged from moderate in the web-based exercise (PABAK 0.49) to good (PABAK 0.8) in the live exercise. Reliability for CD and PD assessments were respectively good and excellent in all exercises (ranged from PABAK 0.61 to 0.79 for CD and 0.88 to 0.95 for PD). The interobserver reliability for the semiquantitative scoring of osteophytes was fair in the live exercise (PABAK 0.36) and moderate in the static exercise (PABAK 0.60).ConclusionsConsensual US definitions were found to be reliable for assessing inflammatory lesions in OA of the foot, while the use of US to assess structural damage requires further studies.
- Published
- 2019
- Full Text
- View/download PDF
245. Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints-an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force
- Author
-
Emilio Filippucci, V. Picerno, Ingrid Möller Parera, Pascal Zufferey, Nemanja Damjanov, Greta Carrara, Esperanza Naredo, Georgios Filippou, Anthony M. Reginato, Lene Terslev, Wolfgang A. Schmidt, C. Toscano, Teodora Serban, Violeta Vlad, Annamaria Iagnocco, Antonella Adinolfi, Maria Antonietta D'Agostino, I. Satulu, Tomas Cazenave, Carlos Pineda, Daryl K. MacCarter, Andrea Delle Sedie, Gaël Mouterde, Panagiotis Bozios, Mihaela C. Micu, Valentina Di Sabatino, Mohamed Mortada, George A W Bruyn, Marwin Gutierrez, Florentin Ananu Vreju, Carlo Alberto Scirè, Mario Enrique Diaz Cortes, Francesco Porta, Frédérique Gandjbakhch, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Rhumatologie, Assistance Publique - Hôpitaux de Marseille (APHM)-Institut du Mouvement et de l'appareil Locomoteur (IML), Gènes HLA-DR, Autoanticorps et Microchimérisme dans la Polyarthrite Rhumatoïde et la Sclérodermie (HLA-DR), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie [Rennes] = Rheumatology [Rennes], CHU Pontchaillou [Rennes], Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Rhumatologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de Référence pour les Maladies Systémiques Autoimmunes Rares, Centre Hospitalier du Mans, CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Lapeyronie [Montpellier] (CHU), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de rhumatologie, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Hôpital Roger Salengro [Lille], CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Lariboisière-Fernand-Widal [APHP], Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques (BIOSCAR (UMR_S_1132 / U1132)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), CHU Toulouse [Toulouse], Service de Rhumatologie [CHU Gabriel-Montpied], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Rhumatologie [CHU Pitié Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Filippou, G, Scire, C, Adinolfi, A, Damjanov, N, Carrara, G, Bruyn, G, Cazenave, T, D'Agostino, M, Delle Sedie, A, Di Sabatino, V, Diaz Cortes, M, Filippucci, E, Gandjbakhch, F, Gutierrez, M, Maccarter, D, Micu, M, Moller Parera, I, Mouterde, G, Mortada, M, Naredo, E, Pineda, C, Porta, F, Reginato, A, Satulu, I, Schmidt, W, Serban, T, Terslev, L, Vlad, V, Vreju, F, Zufferey, P, Bozios, P, Toscano, C, Picerno, V, Iagnocco, A, Università degli Studi di Ferrara (UniFE), Università degli Studi di Siena = University of Siena (UNISI), University of Belgrade [Belgrade], MC Groep Hospitals, Lelystad, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of Pisa - Università di Pisa, Università Politecnica delle Marche [Ancona] (UNIVPM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universidad Autonoma Metropolitana - Iztapalapa, Instituto Nacional de Rehabilitacion, Rheumatology, North Valley Hospital, Whitefish, Montana, Facultat de Medicina [Barcelona], Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Zagazig University, and Universidad Autónoma de Madrid (UAM)
- Subjects
Male ,Wrist Joint ,Genetics and Molecular Biology (all) ,Settore MED/16 - REUMATOLOGIA ,Gout ,chondrocalcinosis ,osteoarthritis ,ultrasonography ,[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging ,International Cooperation ,Triangular fibrocartilage ,MESH: Wrist Joint ,Urate lowering therapy ,Osteoarthritis ,MESH: Observer Variation ,Biochemistry ,MESH: Uric Acid ,Metacarpophalangeal Joint ,chemistry.chemical_compound ,0302 clinical medicine ,Medicine ,Acromioclavicular joint ,Immunology and Allergy ,030212 general & internal medicine ,skin and connective tissue diseases ,Observer Variation ,MESH: Aged ,MESH: Middle Aged ,Ultrasound ,Calcium pyrophosphate ,MESH: Follow-Up Studies ,Middle Aged ,Management ,MESH: Reproducibility of Results ,MESH: Internet ,medicine.anatomical_structure ,Radiology Information Systems ,Acromioclavicular Joint ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Rheumatology ,Immunology ,Biochemistry, Genetics and Molecular Biology (all) ,MESH: Radiology Information Systems ,osteoarthriti ,Female ,Hip Joint ,Flare ,MESH: Hip Joint ,musculoskeletal diseases ,General Biochemistry, Genetics and Molecular Biology ,NO ,03 medical and health sciences ,chondrocalcinosi ,Humans ,MESH: Metacarpophalangeal Joint ,MESH: Chondrocalcinosis ,Aged ,030203 arthritis & rheumatology ,Reproducibility ,Internet ,MESH: Symptom Flare Up ,MESH: Gout Suppressants ,MESH: Humans ,business.industry ,Prophylaxis ,MESH: Gout ,Reproducibility of Results ,MESH: Acromioclavicular Joint ,medicine.disease ,MESH: Male ,MESH: Prospective Studies ,MESH: International Cooperation ,chemistry ,sense organs ,business ,Nuclear medicine ,MESH: Female ,Chondrocalcinosis ,Kappa ,MESH: Ultrasonography - Abstract
Objectives To assess the reliability of the OMERACT ultrasound (US) definitions for the identification of calcium pyrophosphate deposition disease (CPPD) at the metacarpal-phalangeal, triangular fibrocartilage of the wrist (TFC), acromioclavicular (AC) and hip joints. Methods A web-based exercise and subsequent patient-based exercise were carried out. A panel of 30 OMERACT members, participated at the web-based exercise by evaluating twice a set of US images for the presence/absence of CPPD. Afterwards, 19 members of the panel met in Siena, Italy, for the patient-based exercise. During the exercise, all sonographers examined twice eight patients for the presence/absence of CPPD at the same joints. Intraoberserver and interobserver kappa values were calculated for both exercises. Results The web-based exercise yielded high kappa values both in intraobserver and interobserver evaluation for all sites, while in the patient-based exercise, inter-reader agreement was acceptable for the TFC and the AC. TFC reached high interobserver and intraobserver k values in both exercises, ranging from 0.75 to 0.87 (good to excellent agreement). AC reached moderate kappa values, from 0.51 to 0.85 (moderate to excellent agreement) and can readily be used for US CPPD identification. Conclusions Based on the results of our exercise, the OMERACT US definitions for the identification of CPPD demonstrated to be reliable when applied to the TFC and AC. Other sites reached good kappa values in the web-based exercise but failed to achieve good reproducibility at the patient-based exercise, meaning the scanning method must be further refined.
- Published
- 2018
- Full Text
- View/download PDF
246. Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database
- Author
-
José Luis Andreu, Alexandra Balbir-Gurman, Roger Hesselstrand, Simona Rednic, Mohammed Tikly, G. Riemekasten, Paola Caramaschi, Serena Vettori, Marco Matucci-Cerinic, Dominique Farge, Yannick Allanore, Nemanja Damjanov, L. Czirják, Ada Corrado, Beatriz Joven, Loreto Carmona, Estíbaliz Loza, Paolo Airò, Ulrich A. Walker, Oliver Distler, Patricia Carreira, Lidiya P. Ananieva, Carreira, Pe, Carmona, L, Joven, Be, Loza, E, Andréu, Jl, Riemekasten, G, Vettori, S, Balbir-Gurman, A, Airò, P, Walker, U, Damjanov, N, Matucci-Cerinic, M, Ananieva, Lp, Rednic, S, Czirják, L, Distler, O, Farge, D, Hesselstrand, R, Corrado, A, Caramaschi, P, Tikly, M, and Allanore, Y
- Subjects
Adult ,Male ,medicine.medical_specialty ,Databases, Factual ,Cross-sectional study ,Immunology ,Disease ,Scleroderma ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,Rheumatology ,Internal medicine ,Cardiac conduction ,Prevalence ,medicine ,Humans ,Immunology and Allergy ,Registries ,030212 general & internal medicine ,Age of Onset ,Sex Distribution ,skin and connective tissue diseases ,Retrospective Studies ,030203 arthritis & rheumatology ,Scleroderma, Systemic ,integumentary system ,business.industry ,Incidence ,Incidence (epidemiology) ,Age Factors ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,3. Good health ,Europe ,Cross-Sectional Studies ,Female ,Age of onset ,business - Abstract
Objective: The aim of this study was to analyse differences in clinical presentation in patients with early (< 3 years’ duration) systemic sclerosis (SSc), comparing three age groups according to disease subsets. Method: Cross-sectional analysis of the prospective EULAR Scleroderma Trials and Research database (EUSTAR) was performed. Patients fulfilling preliminary American College of Rheumatology 1980 classification criteria for SSc, with < 3 years from the first non-Raynaud’s SSc symptom at first entry, were selected. Patients with < 3 years from the first SSc symptom, including Raynaud’s phenomenon, were also analysed. SSc-related variables, including antibodies, SSc subsets, and organ involvement, were examined. Age was categorized into ≤ 30, 31–59, and ≥ 60 years. We performed descriptive and bivariate analyses. Results: The study included 1027 patients: 90% Caucasian, 80% women, and 40% with diffuse disease. In early stages of SSc, younger patients had significantly more anti-Scl-70 antibodies and diffuse disease. With increasing age, we observed more elevation of estimated pulmonary systolic pressure on echocardiography (5%, 13%, and 30%, respectively, in the three age groups), cardiac conduction blocks (6%, 6%, and 15%), and left ventricular diastolic dysfunction (4%, 12%, and 27%). The results were similar for 650 patients with < 3 years from first SSc symptom, including Raynaud’s. Conclusion: In early stages of SSc, older patients showed data indicating more severe disease with greater cardiac involvement. The diffuse subset was more frequent in the younger subgroup. The identification of such differences may help in selecting appropriate management for individual patients in clinical practice. (Less)
- Published
- 2018
247. Systemic sclerosis impacts right heart and cardiac autonomic nervous system
- Author
-
Cesare Cuspidi, Nemanja Damjanov, Marijana Tadic, Maja Zlatanovic, Vera Celic, Vesna Kocijancic, Ana Stevanovic, Tadic, M, Zlatanovic, M, Cuspidi, C, Stevanovic, A, Celic, V, Damjanov, N, and Kocijancic, V
- Subjects
Male ,medicine.medical_specialty ,Longitudinal strain ,Systemic sclerosis, right heart , cardiac autonomic nervous system ,Echocardiography, Three-Dimensional ,Physical examination ,030204 cardiovascular system & hematology ,Autonomic Nervous System ,Free wall ,03 medical and health sciences ,0302 clinical medicine ,Heart Rate ,Internal medicine ,medicine ,Heart rate variability ,Humans ,Radiology, Nuclear Medicine and imaging ,030203 arthritis & rheumatology ,Ejection fraction ,Scleroderma, Systemic ,integumentary system ,medicine.diagnostic_test ,Ventricular Remodeling ,business.industry ,Middle Aged ,Autonomic nervous system ,Echocardiography ,Right heart ,Rv function ,Cardiology ,Electrocardiography, Ambulatory ,Ventricular Function, Right ,Female ,business - Abstract
Aim To evaluate the influence of systemic sclerosis (SSc) on right ventricular (RV) remodeling by two- and three-dimensional echocardiography (2DE and 3DE) and heart rate variability (HRV). Methods Forty-five SSc patients and 35 age- and gender-matched healthy controls underwent clinical examination, 24-h Holter monitoring, and comprehensive 2DE and 3DE. Results 2DE RV global and RV free wall longitudinal strains, as well as 2DE RV endocardial, mid-myocardial, and epicardial longitudinal strains were lower in SSc subjects, who exhibited greater 3DE RV volumes but lower 3DE RV ejection fraction than controls. HRV indices were impaired in SSc subjects. These differences in RV global and free wall longitudinal strain, layer-specific strains, and ejection fraction, were associated with HRV indices independently of demographic, clinical, and echocardiographic parameters. Modified Rodnan Skin Score, clinical indicator of skin involvement in SSc, was associated with HRV parameters, RV layer-specific mechanics, and RV ejection fraction. Conclusion SSc affects RV function and mechanics of all myocardial layers, as well as cardiac autonomic nervous function. HRV indices are significantly associated with RV function, RV deformation, and skin involvement in SSc patients.
- Published
- 2017
248. Definition and Reliability Assessment of Elementary Ultrasonographic Findings in Calcium Pyrophosphate Deposition Disease: A Study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force
- Author
-
Greta Carrara, Marwin Gutierrez, Carlo Alberto Scirè, Esperanza Naredo, V. Picerno, Francesco Porta, George A W Bruyn, Emilio Filippucci, Nemanja Damjanov, Ingrid Möller, Mihaela C. Micu, Pascal Zufferey, Carlos Pineda, Violeta Vlad, Annamaria Iagnocco, Antonella Adinolfi, Wolfgang A. Schmidt, Lene Terslev, C. Toscano, Andrea Delle Sedie, Georgios Filippou, Maria Antonietta D'Agostino, Filippou, G, Scire, C, Damjanov, N, Adinolfi, A, Carrara, G, Picerno, V, Toscano, C, Bruyn, G, D'Agostino, M, Delle Sedie, A, Filippucci, E, Gutierrez, M, Micu, M, Moller, I, Naredo, E, Pineda, C, Porta, F, Schmidt, W, Terslev, L, Vlad, V, Zufferey, P, and Iagnocco, A
- Subjects
musculoskeletal diseases ,Wrist Joint ,medicine.medical_specialty ,Settore MED/16 - REUMATOLOGIA ,Delphi Technique ,Knee Joint ,Immunology ,Chondrocalcinosis ,Osteoarthritis ,Wrist ,NO ,Tendons ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Rheumatology ,Synovial Fluid ,medicine ,Immunology and Allergy ,Synovial fluid ,Humans ,030212 general & internal medicine ,Ultrasonography ,030203 arthritis & rheumatology ,Hyaline cartilage ,business.industry ,Calcium pyrophosphate ,Reproducibility of Results ,medicine.disease ,Ultrasonography knee osteoarthritis ,Tendon ,Ultrasonography knee osteoarthriti ,Chondrocalcinosi ,medicine.anatomical_structure ,Hyaline Cartilage ,chemistry ,Physical therapy ,Fibrocartilage ,Osteoarthriti ,Nuclear medicine ,business - Abstract
Objective.To define the ultrasonographic characteristics of calcium pyrophosphate crystal (CPP) deposits in joints and periarticular tissues and to evaluate the intra- and interobserver reliability of expert ultrasonographers in the assessment of CPP deposition disease (CPPD) according to the new definitions.Methods.After a systematic literature review, a Delphi survey was circulated among a group of expert ultrasonographers, who were members of the CPPD Ultrasound (US) Outcome Measures in Rheumatology (OMERACT) subtask force, to obtain definitions of the US characteristics of CPPD at the level of fibrocartilage (FC), hyaline cartilage (HC), tendon, and synovial fluid (SF). Subsequently, the reliability of US in assessing CPPD at knee and wrist levels according to the agreed definitions was tested in static images and in patients with CPPD. Cohen’s κ was used for statistical analysis.Results.HC and FC of the knee yielded the highest interobserver κ values among all the structures examined, in both the Web-based (0.73 for HC and 0.58 for FC) and patient-based exercises (0.55 for the HC and 0.64 for the FC). Kappa values for the other structures were lower, ranging from 0.28 in tendons to 0.50 in SF in the static exercise and from 0.09 (proximal patellar tendon) to 0.27 (triangular FC of the wrist) in the patient-based exercise.Conclusion.The new OMERACT definitions for the US identification of CPPD proved to be reliable at the level of the HC and FC of the knee. Further studies are needed to better define the US characteristics of CPPD and optimize the scanning technique in other anatomical sites.
- Published
- 2017
249. The relationship between left ventricular deformation and heart rate variability in patients with systemic sclerosis: Two- and three-dimensional strain analysis
- Author
-
Nemanja Damjanov, Marijana Tadic, Vesna Kocijancic, Branislava Ivanovic, Maja Zlatanovic, Ana Stevanovic, Vera Celic, Cesare Cuspidi, Tadic, M, Zlatanovic, M, Cuspidi, C, Ivanovic, B, Stevanovic, A, Damjanov, N, Kocijancic, V, and Celic, V
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cross-sectional study ,Echocardiography, Three-Dimensional ,Physical examination ,Strain (injury) ,030204 cardiovascular system & hematology ,Ventricular Function, Left ,Strain ,Systemic sclerosi ,03 medical and health sciences ,Ventricular Dysfunction, Left ,0302 clinical medicine ,Heart Rate ,Internal medicine ,Heart rate ,medicine ,Heart rate variability ,Humans ,030203 arthritis & rheumatology ,Scleroderma, Systemic ,integumentary system ,medicine.diagnostic_test ,business.industry ,Stroke Volume ,Stroke volume ,Left ventricle ,Middle Aged ,medicine.disease ,Autonomic nervous system ,Cross-Sectional Studies ,Echocardiography ,Cardiology ,Population study ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objective We sought to investigate left ventricular (LV) function and deformation, as well as heart rate variability (HRV), and their relationship, in patients with systemic sclerosis (SSc). Methods The study included 49 SSc patients and 38 age-matched healthy subjects. All patients underwent clinical examination, serological tests, 24-h Holter monitoring, and comprehensive two- and three-dimensional echocardiography (2DE and 3DE). Results 2DE and 3DE LV global longitudinal and circumferential strain, as well as 3DE area strains are significantly reduced in SSc patients comparing with controls. 2DE and 3DE LV radial strains are similar between the observed groups. 2DE LV layer-specific longitudinal and circumferential strains are also significantly affected by SSc. Parameters of cardiac autonomic nervous system, assessed by HRV indices, SDNN, SDANN, rMMSD, p50NN, 24-h HF, LF and TP are significantly lower in SSc group. HRV indices (24-h HF and LF) are associated with 2DE LV global, 2DE LV layer-specific and 3DE LV mechanics independently of main demographic, clinical and echocardiographic parameters of the study population. Additionally, Modified Rodnan Skin Score, clinical parameter of skin involvement in SSc, is significantly associated with HRV (24-h HF and LF), 2DE and 3DE LV deformation. Conclusion SSc significantly impacts LV deformation, all myocardial layers, and cardiac autonomic nervous function. A significant association between cardiac autonomic nervous system function, skin involvement and LV mechanics is revealed in SSc patients. These findings should encourage detailed cardiac assessment and further cardiac follow-up of the SSc patients with higher skin involvement, even when traditional echocardiographic parameters are within normal range.
- Published
- 2016
250. The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology
- Author
-
Emmanuel Maheu, Carlo Alberto Scirè, Marco Matucci Cerinic, Xavier Chevalier, Nemanja Damjanov, Bruno Frediani, Luigi Di Matteo, Demirhan Diracoglu, Emanuele Bizzi, Rasho Rashkov, Durda Babic-Naglic, Spiros Aslanidis, Natalia Martusevich, Greta Carrara, Giovanni Minisola, Alberto Migliore, Gabriel Herrero-Beaumont, Gerolamo Bianchi, Jose Vicente Moreno Muelas, Gian Filippo Bagnato, Ruxandra Ionescu, Roberta Ramonda, Nurullah Akkoc, L. Denisov, L. Collaku, M. Scarpellini, Loreto Carmona, Tatiana Barskova, Jaime Branco, Migliore, A, Scire, C, Carmona, L, Beaumont, G, Bizzi, E, Branco, J, Carrara, G, Chevalier, X, Collaku, L, Aslanidis, S, Denisov, L, Di Matteo, L, Bianchi, G, Diracoglu, D, Frediani, B, Maheu, E, Martusevich, N, Bagnato, G, Scarpellini, M, Minisola, G, Akkoc, N, Ramonda, R, Barskova, T, Babic-Naglic, D, Muelas, J, Ionescu, R, Rashkov, R, Damjanov, N, and Cerinic, M
- Subjects
Male ,Time Factors ,Delphi Technique ,Delphi method ,Osteoarthritis ,Knee Joint ,0302 clinical medicine ,Risk Factors ,Early diagnosis ,Knee joint ,Referral ,Female ,Focus Groups ,Humans ,Italy ,Osteoarthritis, Knee ,Qualitative Research ,Referral and Consultation ,Rheumatology ,Societies, Medical ,Symptom Assessment ,Consensus ,Early Diagnosis ,Immunology and Allergy ,Immunology ,Medicine ,030212 general & internal medicine ,Generalized pain ,Early diagnosi ,Systematic review ,Osteoarthriti ,medicine.symptom ,musculoskeletal diseases ,medicine.medical_specialty ,NO ,03 medical and health sciences ,Medical ,Internal medicine ,Knee ,030203 arthritis & rheumatology ,business.industry ,medicine.disease ,Knee pain ,Physical therapy ,Societies ,business - Abstract
The aim of this study was to establish consensus for potential early symptomatic knee osteoarthritis (ESKOA) clinical definition and referral criteria from primary care to rheumatologists, based on available data from literature and a qualitative approach, in order to perform studies on patients fulfilling such criteria and to validate the obtained ESKOA definition. A complex methodological approach was followed including: (1) three focus groups (FG), including expert clinicians, researchers and patients; (2) a systematic literature review (SLR); (3) two discussion groups followed by a Delphi survey. FG and SLR were performed in parallel to inform discussion groups in order to identify relevant constructs to be included in the modified Delphi survey. ESKOA is defined in the presence of: (a) two mandatory symptoms (knee pain in the absence of any recent trauma or injury and very short joint stiffness, lasting for less than 10min, when starting movement) even in the absence of risk factors, or (b) knee pain, and 1 or 2 risk factors or (c) three or more risk factors in the presence of at least one mandatory symptom, with symptoms lasting less than 6 months. These criteria are applicable in the absence of active inflammatory arthritis, generalized pain, Kellgren-Lawrence grade >0, any recent knee trauma or injury, and age lower than 40years. Knee pain in the absence of any recent trauma lasting for less than 6months was considered as the referral criterion to the rheumatologist for the suspicion of ESKOA. This consensus process has identified provisional clinical definition of ESKOA and defined potential referral criterion to rheumatologist, in order to test ESKOA obtained definition in prospective validation studies.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.